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1 Summary 
TRPM3 proteins belong to the large family of Transient receptor potential (TRP) proteins, 
which are involved of a wide variety of physiological functions. TRPM3 as well as other 
members of TRP proteins are thought to assemble into homo- or hetero-tetrameric 
complexes to build ion-conducting channels in the plasma membrane. TRPM3 build 
ionotropic steroid receptors that are activated by the neurosteroid pregnenolone sulfate 
(PregS) and efficiently blocked by flavanones like Hesperetin. TRPM3 channels are 
expressed in pancreatic β-cells and dorsal root ganglion neurons where they are involved in 
insulin secretion and pain perception, respectively. TRPM3 transcripts are also expressed in 
the pituitary gland and a plethora of other cells and tissues. However, their function in these 
tissues is still unknown. 
Cloning of 98 cDNAs from mouse pituitaries identified 12 different variants that differed in 
exon 8, 13, 15, 17 and 20 but not in the pore-coding exon 24. Western blots and RT-PCR 
analysis confirmed expression of TRPM3 transcripts and proteins in the pituitary gland of the 
mouse and indicated TRPM3 expression in both neuro- and adeno-pituitary. Accordingly, 
knock-in mice expressing the green fluorescent protein under the control of the TRPM3 
promoter displayed prominent GFP-expression in the posterior lobe (PL), weaker expression 
in the intermediate lobe (IL) as well as expression in single cells of the anterior lobe (AL). 
Detailed immunohistochemical analysis indicated TRPM3 expression in folliculostellate cells 
(FS) of the AL, pituicytes of the PL and finally in melanocyte-stimulating hormone (α-MSH) 
releasing cells (melanotrophs) of the IL. 
Fura-2 imaging experiments uncovered PregS-induced Ca2+ entry in both AL- and IL/PL cells 
that was blocked in the presence of Hesperetin. Consistently, we detected 
PregS/Hesperetin-sensitive currents in melanotrophs that largely resembled currents through 
recombinant TRPM3 channels and that were not detectable in melanotrophs from TRPM3-
deficient mice. The data demonstrate expression of functional TRPM3 channels in α-MSH 
secreting cells and provide the basis for a deeper understanding of their biological role in the 
pituitary gland. 
Zusammenfassung 
TRPM3 Proteine zählen zur großen Familie der Transient Rezeptor Potential (TRP)-Proteine, 
die eine Vielzahl unterschiedlicher physiologischer Funktionen besitzen. TRPM3-Proteine 
lagern sich vermutlich zu homo-oder hetero-tetrameren Kanalkomplexen zusammen und 
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bilden auf diese Weise ionenleitende Poren in der Plasmamembran. TRPM3 bildet ionotrope 
Steroidrezeptoren, die durch das Neurosteroid Pregnenolonsulfat (PregS) aktiviert und 
umgekehrt effizient durch Flavanone wie Hesperetin blockiert werden. TRPM3-Kanäle 
werden in pankreatischen β-Zellen und Neuronen der Hinterwurzelganglien exprimiert, wo 
sie an der Insulinsekretion bzw- Schmerzwahrnehmung beteiligt sind. TRPM3-Transkripte 
werden auch in der menschlichen Hypophyse und einer Vielzahl von anderen Zellen und 
Geweben exprimiert. Allerdings ist ihre Funktion in diesen Geweben noch unbekannt. 
Die Klonierung von 98 unterschiedlichen cDNA-Transkripten aus der Maushypophyse 
identifizierte 12 unterschiedliche Spleißvarianten die sich in Exon 8, 13, 15, 17 und 20 nicht 
jedoch  im porencodierenden Exon 24 unterschieden. Western Blots und RT-PCR-Analysen 
bestätigten die Expression von TRPM3-Transkripten und Proteinen in der Hypophyse der 
Maus sowohl in der Neuro- als auch in der Adenohypophyse. Im Übereinstimmung mit 
diesen Ergebnissen  zeigten Knock-in Mäuse, die das grün-fluoreszierende Protein (GFP) 
unter der Kontrolle des TRPM3-Promoters exprimierten, starke GFP-Expression im 
Hypophysenhinterlappen (HHL) sowie schwächere Expression im 
Hypophysenzwischenlappen (HZL) und Hypophysenvorderlappen (HVL). Detaillierte 
immunohistochemische Analysen zeigten TRPM3-Expression in follikulostellaren (FS) Zellen 
des HVLs, in Pituizyten des HHLs und in Melanozyten-stimulierendes Hormon (α-MSH)-
sekretierenden Zellen (melanotrope) des HZLs. Ca2+-Imaging Experimente mit Fura-2 
zeigten einen PregS-induzierten Ca2+-Einstrom in Zellpräparten des HVLs- und aus 
HZL/HHLs, der in Gegenwart von Hesperetin gehemmt war. Dem entsprechend zeigten 
Patch-Clamp-Messungen PregS/Hesperetin-sensitive Ströme in melanotropen Zellen. Die 
biophysikalischen Charakteristika dieser Ströme entsprachen dem Strom durch 
rekombinante TRPM3-Kanäle. Solche Ströme waren in melanotropen Zellen aus TRPM3-
defizienten Mäusen nicht nachweisbar.   
Die Ergebnisse demonstrieren die Expression von funktionstüchtigen TRPM3-Kanälen in α-
MSH- sekretierenden Zellen und bilden die Grundlage zur Untersuchung der biologischen 
Rolle von TRPM3-Ionenkanälen in der Hypophyse. 
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2 Introduction 
2.1 The pituitary gland 
The pituitary gland is a central endocrine gland that plays a key role in the maintenance of 
body homeostasis and regulates basic physiological functions including growth and 
reproduction. The functions of the gland itself are regulated by hypothalamic hormones 
synthesized in the cell bodies of the hypothalamic neurons. 
2.1.1 Anatomy and histology of the pituitary gland 
The pituitary gland or hypophysis is a small gland located at the basis of the brain in a tiny 
bony cavity of the sphenoid bone of the skull called sella turcica [1]. The pituitary gland is 
anatomically and functionally connected to the hypothalamus by the median eminence via 
the infundibular stalk (Figure  2-1). Structurally, the pituitary gland comprises two 
morphologically, embryologically and functionally distinct lobes, namely the adenohypophysis 
(or anterior lobe) and the neurohypophysis (or the posterior lobe). The adenohypophysis is 
pinkish in color and built up of soft, friable granular tissue, whereas the neurohypophysis is 
white, firmer and more fibrous. The adenohypophysis is composed of two parts: pars 
tuberalis and pars distalis (Figure  2-1). The pars tuberalis forms a collar of cells surrounding 
the external region of the lower hypophysial stalk. The pars distalis or anterior lobe is the 
largest part and comprises 80 % of the gland [1]. Five types of endocrine cells that can be 
stained by acidic or basic chromophors can be distinguished in the anterior pituitary 
depending on the hormones that they release. Corticotrophs comprise 15-20 % of the 
anterior lobe cells and produce adrenocorticotropic hormone (ACTH) by the cleavage of the 
precursor polypeptide pro-opiomelanocortin (POMC).  Gonadotrophs comprise 10-15 % of all 
anterior pituitary cells and release luteinizing hormone (LH) or follicle stimulating hormone 
(FSH) or both.  Thyrotrophs comprise 10 % of the anterior pituitary all population and release 
thyroid stimulating hormone (TSH). Somatotrophs or growth hormone (GH) releasing cells 
comprise 30-50 % of all anterior pituitary cells and finally, lactotrophs or prolactin (PRL) 
releasing cells comprise 15-20 % of the anterior pituitary cells [2,3].  
In addition to endocrine cells, the anterior pituitary contains chromophobic, non-endocrine 
cells. Folliculostellate cells (FS cells) comprise 5-10 % of anterior pituitary cell population [1]. 
FS cells were first described 60 years ago by Rinehart and Farquhar [4] and were thought to 
be derived from the neuroectoderm [5]. As the name indicates, FS cells have star-shaped 
morphology and express the protein S100B, a glial-specific intracellular calcium binding 
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protein which is primarily expressed in astrocytes [6]. FS-cells were also described to 
express other astrocytic proteins like the glial fibrillary acidic protein (GFAP) [7] and the 
glutamate aspartate transporter (GLAST) [8]. FS cells are organized in a three dimensional 
network capable to perform intercellular communication between endocrine cells via gap 
junction-mediated signals [9]. 
The pars intermedia or the intermediate lobe is located in the marginal area between anterior 
and posterior pituitary and has been considered to be part of the adenohypophysis in 
humans due to its rudimentary structure. In vertebrates other than human, the pars 
intermedia contains a single endocrine cell type, the melanotrophs, which are also POMC-
producing cells that release alpha-melanocyte-stimulating hormone (α-MSH) and β-
endorphin. In addition, two non-endocrine glial cell types, the marginal cells and the 
astrocyte-like cells, are also localized in the pars intermedia [1].  
The neurohypophysis is composed of the median eminence of the hypothalamus, the 
infundibular stem which forms the inner part of the stalk and the infundibular process or the 
posterior lobe. The posterior lobe is composed mainly of the axonal terminals of the 
magnocellular neurosecretory cells (MNCs) originating from the hypothalamic supraoptic 
(SON) and paraventrical (PVN) nuclei. The axons of these neurons project caudally and 
medially to collect in the hypothalamo-neurohypophysial tract passing the median eminence 
to reach the neurohypophysis. The axons ramify into branches and these branches are 
divided to give rise to nerve terminals of 3 µm diameter. In addition to the small nerve 
terminals, neuro-secretory axonal swellings (Herring bodies) of 6-8 µm in diameter are 
formed due to the accumulation of hormones and their carrier molecules in dense vesicles 
[10]. Vasopressin (VP) and its carrier molecule neurophysin II as well as oxytocin (OXT) and 
its carrier molecule neurophysin I are released from the nerve endings to the systemic 
circulation. Pituicytes, a special type of glial cells, are the only resident cell type in the 
posterior lobe and they are normally found around axonal terminals. Like the FS cells, 
pituicytes express S100b, GFAP and GLAST [8,11]. In addition to the neurosecretory nerve 
terminals, a smaller number of non-neurosecretory axons terminate in the posterior lobe.  
Both types of axons were shown to terminate in a synaptoid contact with pituicytes [10]. 
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Figure  2-1: Scheme of a midsagittal section of the human pituitary gland [12]. 
The main parts of the pituitary gland are illustrated as well as the blood supply to the pituitary. 
Hypothalamic neuron indicated by its gray soma represents a magnocellular neuron releasing 
vasopressin which ends in the posterior lobe. Neurons 1 and 2 are secreting releasing factors into 
capillary networks that give rise to the long and short hypophyseal portal vessels, respectively. 
Releasing hormones are shown reaching the hormone-secreting cells of the anterior lobe via the 
portal vessels. 
2.1.2 Regulation and function of hormone-releasing pituitary cells 
Due to its central role in hormone regulation of the body, the primary functions of the pituitary 
cells are defined by the hormones that they secrete. In addition, a number of non-secreting 
cells exist in the pituitary that play important but sometimes neglected and indirect roles in 
hormone secretion. 
2.1.2.1 Somatotrophs  
Somatotrophs release GH which is essential for growth during the first few months after birth 
and for the maintenance of normal growth rate during childhood. GH exerts its function by 
stimulation of Insulin-Like Growth Factor-I (IGF-1) synthesis in the liver and other tissues 
[13]. Following early childhood and prior to adolescence, IGF-1 mediates longitudinal bone 
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growth, skeletal maturation, and acquisition of bone mass, whereas in adults it is important in 
the maintenance of bone mass [14]. In addition, GH plays an important role in fat and 
carbohydrates metabolism [15]. GH release is regulated by two different hypothalamic 
regulators; growth hormone-releasing hormone (GHRH) which increases GH release and 
somatotropin-releasing inhibitory factor (SRIF) or somatostatin which decreases GH release. 
The signaling cascade of GHRH is initiated by binding to the Gs-protein coupled GHRH 
receptor in the plasma membrane of the somatotrophs. The binding activates adenylyl 
cyclase leading to an increase in the cyclic adenosine monophosphate (cAMP) concentration 
[16]. cAMP increases the activity of protein kinase A (PKA) to phosphorylate proteins 
responsible to increase GH secretion and GH gene expression [17,18]. In addition, 
stimulation of GHRH receptors leads to an elevated [Ca2+]i. Somatostatin decreases GH 
release by binding to inhibitory Gi-proteins coupled to adenylyl cyclase and decreases the 
intracellular calcium concentrations [Ca2+]i. Furthermore, GH release is also regulated by 
peripheral regulators including IGF-1 and ghrelin via Ca2+-dependent mechanisms [19-21]. 
2.1.2.2 Lactrotrophs 
Lactotrophs release prolactin (PRL) that regulates the lactation process and milk synthesis in 
all mammals. PRL induces the growth of mammary glands and their differentiation 
(mammogenesis), milk production by alveolar cells (lactogenesis) and the maintenance of 
lactation (galactopoiesis) [22].  PRL release is mainly regulated by hypothalamic dopamine. 
Dopamine binds to D2 receptors in lactotrophs, inhibits cAMP and Ca2+ signaling pathways 
and thereby inhibiting PRL release [2,23]. Other different inhibitory factors including gamma 
amino butyric acid and gonadotropin-associated peptide have been proposed to inhibit PRL 
release [2]. Thyrotropin-releasing hormone (TRH) is also identified as a PRL-releasing factor 
with unclear stimulation mechanism [24].  Many other peptides were suggested to promote 
PRL release such as oxytocin, hypothalamic vasoactive intestinal peptide (VIP) and 
endothelin [25]. 
2.1.2.3 Gonadotrophs 
Gonadotrophs release LH and FSH which are the main regulators of the reproductive system 
including sperm/ova production and sexual hormone release. In males, LH controls the 
synthesis and the release of testosterone via binding to G-protein coupled receptors on 
testicular Leydig cells and activating cAMP signaling pathway [26]. The role of FSH in males 
is not well defined, however it is well documented that FSH binds to its receptors in Sertoli 
cells and increases the production of androgen binding proteins which may support 
spermatogenesis [27]. In females, FSH stimulates the growth of ovarian follicles, whereas LH 
induces ovulation and regulates the secretion of progesterone from the corpus luteum.  Both 
Introduction  
 
 
 7 
LH and FSH regulate follicular steroidogenesis and androgen and estradiol secretion [12]. 
The two major regulators of the release of gonadotropins are the hypothalamic gonadotropin-
releasing hormones (GnRH) and the feedback of the gonadal factors. GnRH reaches the 
anterior lobe through the hypophysial portal system and promotes a Ca2+-dependent pulsatile 
secretion of gonadotropines. GnRH binds to its receptors on gonadotrophs and activates a 
cascade of intracellular signaling pathways including activation of phospholipase C that leads 
to Ca2+ release and activation of protein kinase C [28]. 
2.1.2.4 Thyrotrophs 
Thyrotrophs release TSH which mainly regulates the synthesis and the release of 
triiodothyronine (T3) and thyroxine (T4) by the thyroid gland. TSH binds to Gs-coupled 
receptors of the thyrocytes and activates cAMP signaling pathways. This leads to an 
increase in iodine transport and expression of thyroglobulin and thyroperoxidase resulting in 
increased thyroid hormones release [29]. T3 and T4 have an important effect on body 
growth, metabolism and differentiation of the central nervous system (CNS). TSH secretion is 
regulated by the hypothalamic thyrotropin- releasing hormone (TRH). TRH binds to Gq- 
coupled receptors on thyrotrophs and leads to a PLC-dependent increase of the intracellular 
Ca2+ concentration which stimulates TSH secretion. DAG promotes the activity of PKC 
enhancing TSH release  [30]. T3 and T4 exert a negative feedback effect on TSH release on 
both the pituitary and hypothalamic level [12].  
2.1.2.5 Corticotrophs  
The major function of corticotrophs is the synthesis and release of ACTH which is the major 
regulator of glucocorticoids synthesis in the zona fasciculate of the adrenal gland. ACTH 
binds to melanocortin-2 receptors (MC2R) that activate cAMP signaling pathways 
(Figure  2-2). ACTH is produced in the corticotrophs from its precursor POMC (Figure  2-2). 
POMC is cleaved by the activity of prohormone convertase PC1 to give rise to six different 
peptides including a N-terminal peptide, the joining peptide (JP), ACTH, β-lipotropin (β-LPH), 
γ-lipotropin (γ-LPH) and β-endorphin (β-end) [31].  
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Figure  2-2: POMC processing by PC1 and PC2.  
The physiological roles of its derivate peptides are also shown, modified from [31]. 
2.1.2.6 Melanotrophs 
Melanotropic cells (Melanotrophs) of the intermediate lobe produces α-MSH that is also 
produced from POMC (Figure  2-2). In humans, this is done in the so-called POMC neurons 
of the hypothalamus [32]. A well-known physiological function of α-MSH is to stimulate the 
melanogenesis after binding to melanocortin 1 receptors (MC1R) in melanocytes [33,34]. 
This leads to an increase of cAMP which in turn regulates the transcription and the function 
of tyrosinase, tyrosine hydroxylase and phenylalanine hydroxylase [35,36]. α-MSH also acts 
in a receptor-independent manner to directly regulate the tyrosinase activity [35]. 
Furthermore,  α-MSH was shown to play a significant role in controlling inflammation and 
immunomodulation in the skin by inhibiting the production of proinflammatory cytokines such 
as interleukin-1 (IL-1), IL-6 and tumor necrosis factor-α (TNF-α), and by upregulation of 
immunosuppressive cytokines such as IL-10 [37]. α-MSH is suggested to be involved in 
energy homeostasis, appetite regulation and inhibition of food intake by binding to MC3R and 
MC4R in the hypothalamus ([32,38,39], Figure  2-2). Recently, α-MSH was also shown to 
modulate the activity of basophilic granulocytes by binding to MC1R causing significant 
suppression of the secretion of the proallergic cytokines IL-4, IL-6, and IL-13 [40]. The 
secretion of α-MSH from the intermediate lobe is controlled by γ-amino butyric acid (GABA) 
and neuropeptide Y (NPY) as well as dopamine (DA) released by subpopulations of 
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hypothalamic neurons (tubero-hypophyseal neurons) that directly terminate in the 
intermediate lobe [41,42]. Dopamine binds to D2-receptors in the plasma membrane of the 
melanotrophs and reduces their synthesis of POMC and the release of POMC-cleavage 
products [43] via a cAMP-dependent pathway [44].   
2.1.2.7 Oxytocin-releasing hypothalamic nerve terminals 
Nerve terminals of the MNCs of the hypothalamus release OXT that is synthetized as a pro-
hormone in their cell bodies. OXT release is associated with neurophysin I release, a carrier 
protein which is transported in vesicles with OXT to the posterior lobe [12]. OXT is essential 
for parturition and lactation. Suckling stimulates sensory nerves in the nipple of the mamma 
which in turn  stimulates oxytocin-releasing MNCs. Released OXT stimulates the contraction 
of myoepithelial cells which surround the milk-laden alveoli resulting in milk ejection. During 
childbirth pain, afferent nerve impulses stimulate OXT release leading to strong contractions 
of the uterus supporting delivery of the newborn and the placenta [2,11]. 
2.1.2.8 Vasopressin-releasing hypothalamic nerve terminals 
Similar to OXT, vasopressin (VP) or anti-diuretic hormone (ADH) is synthetized as a pro-
hormone in the cell bodies of MNCs and packed in dense-core neurosecretory vesicles. The 
pro-hormones are cleaved by the activity of proteolytic enzymes to produce VP and its 
associated peptide neurophysin II. This cleavage takes place during the passage of vesicles 
from the Golgi apparatus to the terminals and swellings of the MNCs in the posterior lobe 
[12]. VP-release via exocytosis is stimulated in response to action potentials initiated in the 
plasma membrane of the MNCs. VP diffuses to the blood stream through fenestrated 
capillaries of the posterior lobe. Dehydration is the major physiological signal that stimulates 
VP release. VP plays an important role in the maintenance of body fluids and the regulation 
of blood osmolality. VP binds to V2 receptors in the plasma membrane of the epithelium of 
the collecting duct of the kidney and increases water reabsorption by increased integration of 
water channels (aquaporins) into the epithelial membrane [2,11]. In addition, parvocellular 
neurons of the PVN and SON terminate in the median eminence and release VP into the 
hypophyseal portal system. VP then stimulates corticotrophs synergistically with CRH to 
produce ACTH [45]. 
2.1.3 Function and regulation of non-endocrine pituitary cells  
2.1.3.1 Pituicytes 
Notwithstanding that pituicytes, the astroglial cells of the posterior lobe, do not secret any 
hormone they are suggested to play an important role in the regulation of neurohypophysal 
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hormone output. Pituicytes undergo a remarkable structural reorganization during increased 
demand of hormone release. Under resting conditions, the axonal terminals and swellings 
are laden with dense core neurosecretory vesicles (filled with hormones and their carrier 
proteins) and are completely engulfed by the processes and membranes of pituicytes. 
Neurosecretory swellings and terminals appear to form a synaptoid contact with the 
pituicytes in which the intermembrane distances are small (15-20 nm). The basal lamina, the 
barrier which separates neurohypophysial parenchyma from the fenestrated blood 
capillaries, is more than 60 % occupied with pituicytes limiting hormone availability to the 
blood stream [10,46]. Under stress conditions, such as dehydration, lactation and parturition, 
pituicytes tend to retract from the blood vessels resulting in a reduction of the number of 
terminals engulfed by pituicytes and a significant increase in neurovascular contact followed 
by a remarkable decrease of the amount of neurosecretory granules in the nerve terminals 
(Figure  2-3). Thus, pituicyte retraction allows more hormones to be released into the blood 
stream. When the demand of hormone release returns to its basal level, pituicytes recover to 
the resting morphology thereby limiting hormone availability. Released VP can act on the 
V1a receptors in the pituicytes and increase [Ca2+]i via the IP3 pathway [47]. Activation of V1a 
receptors induces taurine release from pituicytes. Taurine can act at the nerve terminal as a 
negative feedback inhibitor that inhibits hormone output [48]. Pituicytes release taurine 
selectively in response to hypoosmotic stimulation [46]. 
 
Figure  2-3: Postulated scheme for the modulation of neurohypophysal hormone secretion by 
V1a receptor activation of pituicytes, modified from [49]. 
2.1.3.2  Folliculostellate cells 
Folliculostellate cells of the adenohypophysis are described to form a three dimensional cell 
network, in the meshes of which the endocrine cells reside [5,9,50]. The cells are connected 
by gap junctions and transfer informations such as Ca2+ signals and small diffusible 
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molecules over a long distance in the anterior pituitary providing an efficient communication 
system [9]. Additionally, folliculostellate cells display phagocytotic activity and function as 
scavenger cells [1,51]. A study of Shirasawa and Yamanouchi suggested that FS cells might 
be involved in controlling glutamate level and scavenging toxic ammonia [52]. FS cells 
modulate the function of endocrine cells by producing compounds such as lipocortin-1, which 
play an inhibitory effect on CRH and corticotropin secretion, and follistatin, which regulates in 
a paracrinic manner the production and secretion of FSH from gonadotrophs [53-55]. FS 
cells produce many other bioactive peptides like basic fibroblast growth factor which 
stimulates the growth of lactotrophs [56], and nitric oxide (NO) which might regulate LH 
secretion [57,58]. Recently, FS cells were shown to have the potency to differentiate into 
skeletal muscle cells [50]  supporting an old hypothesis that these cells are suspected to act 
as stem cells in the pituitary gland [58]. 
2.2 Calcium signaling in pituitary cells and regulation of hormone 
release 
Ca2+ plays a crucial role as a second messenger in a variety of cellular processes such as 
proliferation, migration, apoptosis, neuronal excitability, exocytosis and gene expression. The 
Ca2+ concentration inside the cell is 20000-fold lower than its concentration in the 
extracellular space. Since Ca2+ ions don’t bind water tightly and precipitate phosphates, cells 
exclude Ca2+ ions from the cytoplasm to maintain the concentration at ~ 100 nM. Ca2+ signals 
in response to external stimuli, range from Ca2+ spikes which transfer fast responses to Ca2+ 
transients or Ca2+ waves which control slower responses. In principle Ca2+ signals are 
created by two types of reactions: calcium ‘On’ reactions including Ca2+ influx from the 
extracellular space through plasma membrane ion channels and Ca2+ release from the 
endoplasmic reticulum (ER) via Inositol trisphosphate (IP3) receptors while calcium ‘Off’ 
reactions include Ca2+ removal from the cytosol by different pumps and exchangers such as 
the Na+/Ca2+ exchanger (NCX), the plasma-membrane Ca2+-ATPase (PMCA) which extrudes 
Ca2+ to the outside and the endoplasmic reticulum Ca2+-ATPase (SERCA) which pumps Ca2+ 
back into the ER [59,60]. 
In endocrine pituitary cells, an increase in the intracellular Ca2+ concentration above the 
threshold of stimulus-transcription or stimulus-secretion coupling leads to calcium-dependent 
hormone production and/or release [3,61,62]. As endocrine pituitary cells are similar to 
neuronal cells in the expression of different voltage-gated calcium, sodium, potassium and 
chloride channels, they are spontaneously able to fire action potentials which are normally 
associated with an increase at the intracellular calcium concentrations [3]. The electrical 
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activity can be modulated by the stimulation of G protein-coupled receptors (GPCRs). 
Stimulative G-proteins (Gs) stimulate the production of c-AMP by adenylcyclase which in turn 
increases the electrical activity and facilitates Ca2+ entry through voltage-gated channels 
directly or indirectly by c-AMP-dependent kinase activity. Activation of inhibitory (Gi)-coupled 
receptors in endocrine pituitary cells leads to the inhibition of electrical activity and hormone 
release. Gq-coupled receptors or calcium-mobilizing receptors are also expressed in pituitary 
cells and their activation leads to the production of diacylglycerol (DAG) and 1,4,5-
trisphosphate (IP3) which induces Ca2+ release from the ER and subsequently increases 
hormone release. In addition to the voltage-gated channels mentioned above, transcripts of 
many members of transient receptor potential channels (TRP channels) like TRPM3, TRPC1, 
TRPC3, TRPC5 and TRPC7 were shown to be expressed in the pituitary gland [63,64]. 
Signaling through TRP channels may account for hormones production and/or release in a 
direct or an indirect way. 
2.3 TRP ion channels 
Transient receptor potential (TRP) channels are a superfamily of cation channels which 
display, apart from their sequence homology and basic channel architecture, distinct features 
regarding the activation mechanisms, ion selectivity and physiological functions [65]. A 
number of these channels play important roles in sensory physiology ranging from 
thermosensation to osmosensation, mechanosensation, vision, olfaction and audition [66]. 
The trp gene was first characterized in a Drosophila melanogaster mutant with impaired 
phototransduction. A prolonged light stimulation of Drosophila wildtype photoreceptors 
induced a sustained response characterized by an initial and an adaptive phase of the 
receptor potential, while trp-mutated photoreceptors showed only a transient response with a 
quick decay to a basal line [67]. In 1989, the trp gene was cloned by Montell and Rubin [68]. 
The idea that the encoded TRP proteins may build membrane channels was initiated by 
Minke and Selinger [69] and in parallel, Hardie and Minke were able to show that the light-
induced Ca2+ influx is reduced up to 10 fold in trp-mutant flies supporting the idea that TRP 
proteins function as a calcium permeable ion channel [70].  
Trp genes have been identified in different organisms ranging from worms (C.elegans) to 
men [71]. In mammals, 28 TRP proteins have been identified and were classified based on 
their topological similarities [72]. The mammalian superfamily of TRP channels is divided into 
six subfamilies, the canonical (TRPC), vanilloid (TRPV), melastatin (TRPM), ankyrin (TRPA), 
Mucolipin (TRPML) and polycystin (TRPP) channels (Figure  2-4). The TRPC, TRPV, TRPM, 
TRPA and TRPN subfamilies are classified as Group 1 of TRP channels as they show the 
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highest degree of sequence homology to the founding member Drosophila TRP, while the 
TRPP and TRPML subfamilies are classified as Group 2 of TRP channels as they display a 
large extracellular loop between transmembrane domains 1 and 2 and are weakly related to 
group 1 [66,71]. 
 
Figure  2-4: Phylogenetic tree of TRP proteins. 
The dendrogram of vertebrate TRPs includes mostly human TRPs, except for mouse TRPC2 which is 
a pseudo gene in man and zebrafish TRPN1 which has no orthologue in mammals. White text and 
cartoons highlight the TRP proteins from worms and flies. One C.elegans and one Drosophila member 
of each subfamily are included [71]. 
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The TRPC subfamily is composed of seven members sharing up to 40 % amino acid identity 
with each other and with the Drosophila TRP protein [73]. TRPV channels display only ~25 % 
sequence homology to the members of TRPC subfamily [66]. The name vanilloid was used 
since the first known member TRPV1 was identified as ligand-gated ion channel that is 
activated by vanilloids like capsaicin [74]. The TRPM subfamily, which shares ∼20 % amino 
acid sequence identity to TRPC proteins, consists of eight members. The first member 
TRPM1 was initially named Melastatin because its expression appeared to be inversely 
correlated with the metastatic potential of melanoma cells [75]. TRPA1 is the only member of 
its subfamily and was identified in an oncogenic screen of down-regulated genes from 
fibroblasts [76]. The TRPP and TRPML proteins have very low sequence similarity with other 
TRP members and were discovered as mutant genes in autosomal dominant polycystic 
kidney disease (ADPKD) and mucolipidosis type IV (MLIV), respectively [71,77].  
2.3.1 Structure of TRP channel complexes 
TRP proteins contain six transmembrane spanning domains (S1-S6) and a pore forming 
region that is located between S5 and S6 (Figure  2-5). The amino (N) and carboxy (C)-
termini are located in the cytosol and comprise most of the protein.  
 
Figure  2-5: The predicted protein structure of TRP proteins. 
The predicted membrane topology of monomeric TRP polypeptides (left) and the tetrameric channel 
complex (right) are shown. Transmembrane spanning domains that flank the ion conducting pore (P) 
are numbered. (Modified from [78]).  
Other structural features of TRP proteins are illustrated in Figure  2-6. The N-terminal 
domains of TRPC, TRPV and TRPA contain up to 3, 6 and 15, ankyrin (ANK) repeats 
respectively. An ANK repeat domain is a ~33 residue motif consisting of two α-helices 
separated by loops [79]. ANK repeats have been proposed to bind to regulatory molecules 
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like calmodulin and ATP [80]. TRPM channels lack ANK repeats but instead contain a TRPM 
homology region of unknown function. A well conserved block of ~25 residues C-terminal to 
the sixth transmembrane domain, called the TRP domain or TRP box, is present in TRPC, 
TRPM and TRPV proteins [71,81]. TRP domains were shown to be required for 
phosphatidylinositol 4,5-bisphosphate (PIP2)  binding and the regulation of channel gating of 
TRPM8 and TRPV5 channels [82]. Heptead repeat structures called coiled-coil domains, are 
present in some members of TRP channel family [83]. They belong to the best defined 
protein-protein interaction domains with a conserved alpha-helical structure. A coiled-coil 
domain in TRPP2 was suggested to link the protein to PKD1 [84,85]. Coiled-coil domains 
also seem to play a role in the multimerization of TRPM channels [86-88]. The C-terminal 
domains of some TRPM channels (M2, M6 and M7) possess enzyme activity and thus the 
proteins were termed chanzymes [71]. The kinase activity of TRPM7 was thought to 
modulate the channel sensitivity for intracellular cAMP regulation and Mg2+ inhibition [89,90], 
whereas in TRPM6 the function of the kinase domain is still unknown. TRPM2 channels are 
linked to a nucleoside diphosphate pyrophosphatase (NUDIX) domain that possess 
adenosine diphosphate (ADP)-ribose hydrolase activity [81].  
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Figure  2-6: Structure of TRP channels.  
In TRPC and TRPP, the C-terminus contain the EF hand domain which is found in a large family of 
calcium-binding proteins and PDZ (postsynaptic density 95/disc-large/zona occludens) which is a 
common protein interaction motif that joins proteins in signaling complexes. In TRPML and TRPP, the 
ER retention signal is a small domain that has been proposed to maintain the channel in the 
endoplasmic reticulum. The other domains indicated are described in the text. (Modified from [81]).  
Similar to other six transmembrane domain channels, TRP proteins form a tetrameric 
quaternary structure in which the S5 and the S6 domains from each subunit contribute to a 
shared selectivity filter and ion-conducting pore ([71], Figure  2-5). Recently, detailed 
informations about the TRPV1 channel structure has been achieved by cryo-electron 
microscopy of the protein at a resolution close to 3 Å. These data confirmed the predicted 
information about the tetrameric structure of TRP channels and ion conducting pore [91,92]. 
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TRP proteins form channels that control the flux of cations along their electrochemical 
gradients. Cation entry through the channel is regulated by the upper gate or the selectivity 
filter of the channel and the lower gate which is formed by the cytoplasmic end of the S6 
helix [81,93]. Most TRP channels form non-selective ion pores with similar ion permeability 
for Ca2+ and Na+ (permeability ratio PCa/PNa ≤ 10). However, TRPM4, TRPM5 and the 
TRPM3α1-variant are almost impermeable for divalent cations, whereas  TRPV5 and TRPV6 
are highly selective for Ca2+ (PCa/PNa ≥ 100) [94]  
2.3.2 Activation and functional properties of TRP channels 
TRP channels are widely expressed in large number of tissues and cell types. Since TRP 
channels allow the flux of cations through the plasma membrane, they play important roles in 
regulating the intracellular Na+ and Ca2+ concentrations ([Na+]i, [Ca2+]i) and the membrane 
potentials in both excitable and nonexcitable cells [95]. TRP channels are sensitive to a wide 
range of activators and activation mechanisms including changes in temperature, pH, 
osmolality and intracellular second messenger (Table  2-1).Therefore, TRP channels play 
important roles in a plethora of physiological functions including vision, taste, smell, hearing, 
and touch. Table  2-1 shows modes of activation for each individual TRP channel. TRPC 
channels are modulated via a GPCR-mediated pathway including PIP2 hydrolysis and the 
production of DAG and IP3. IP3 binds the IP3 receptors resulting in Ca2+ release from 
intracellular stores which in turn activates cation entry through TRP channels. Other TRP 
channels can be activated from outside by a plethora of agonists. For example, plant 
secondary compounds like capsaicin and icilin activate TRPV1 and TRPM8, respectively. 
Most of these channels also belong to the group of the so-called thermo-TRPs (TRPV1-4, 
TRPA1, TRPM3 and TRPM8) since they are also sensitive to changes of the ambient 
temperature [65]. Finally, a number of channels already display constitutive activity that is 
modulated by a variety of intracellular second messenger. 
Most of the TRP channels are nonselective for mono and divalent cations. However, TRPV1 
and TRPM8 show increased selectivity for divalent cations with a fractional Ca2+ current 
under physiological conditions of 3-5 % [96], others like TRPA1 and TRPM3 display even 
higher fractional Ca2+ currents of about 25 % and finally TRPV5 and TRPV6 are 
extraordinary Ca2+-selective with fractional Ca2+ current close to 100 % [95,97]. The 
activation of TRP channels may trigger gating of voltage-gated Ca2+ channels and/or induce 
Ca2+-dependent channel inactivation. This indicates that the electrogenic effect of TRP 
channel activation might be as important as its contribution to Ca2+ changes by mediating 
Ca2+ entry. Members of the TRPC subfamily are reported to have a significant importance in 
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the regulation of firing pattern of neurons [98]. In non-excitable cells, TRP channels activation 
regulates the driving forces for Ca2+ entry [95]. Finally, TRP proteins like TRPML are also 
located in the intracellular organelles like the ER, endosomes and lysosomes and serve as 
intracellular Ca2+ release channels [95,99]. 
Table  2-1: Properties of channels formed by mammalian TRP proteins. Modified from [71,100]. 
Subtype 
Selectivity 
P Ca/P Na 
Activation/ modulation of 
activity 
Function/ 
Associated diseases 
Consequences of TRP-deletion in 
mice 
TRPC1 ~1 
PLC activation, store depletion, 
conformational coupling, 
mechanical stretch 
Required for EPSC in 
Purkinje cells 
 
Elevated body weight, impaired salivary 
gland fluid secretion 
TRPC2 ~1-3 
PLC activation, diacylglycerol 
(DAG) 
Acrosome reaction, 
Pheromone perception 
Abnormal sexual and mating behavior 
TRPC3 ~1.5 
PLC activation, store depletion, 
conformational coupling, DAG, 
exocytosis 
Modulating neuritis 
extension 
Defects in motor coordination and walking 
behavior 
TRPC4 ~1-8 
PLC activation, store depletion 
(?), PIP2 breakdown, exocytosis 
Vasorelaxation, 
neurotransmitter 
release 
 
Impaired vascular function, altered 5-HT-
mediated GABA 
release, defects in intestinal motility 
TRPC5 ~2-9 
PLC activation, store depletion 
(?), sphingosine-1-phosphate, 
exocytosis 
Modulating neuritis 
extension 
Decreased anxiety-like behavior 
TRPC6 ~5 
PLC activation, conformational 
coupling , DAG, PIP3 
platelet aggregation 
Grossly normal, increased artery 
contractility, impaired light 
response in intrinsically photosensitive 
retinal ganglion cells 
in TRPC6/TRPC7 compound KO mice 
TRPC7 ~1-5 
PLC activation, store depletion, 
DAG 
? 
impaired light 
response in intrinsically photosensitive 
retinal ganglion cells 
in TRPC6/TRPC7 compound KO mice 
TRPV1 ~4-10 
Heat (43˚C), vanilloids, 
proinflammatory cytokines, 
protons, PIP2 
Hot pain sensor 43°C Reduced inflammatory hyperalgesia, 
impaired bladder function 
TRPV2 ~1-3 
Heat (52˚C), osmotic cell 
swelling, exocytosis 
Very hot pain sensor 
52°C 
Accelerated mortality in bacterial infection 
TRPV3 ~1-10 
Warm (33–39˚C); PUFAs; 
menthol; compounds from 
oregano, cloves, and thymes 
Warm temperature 
sensor (30°-39°C) 
Impaired thermosensation, skin barrier 
effects, curved whiskers, and hair 
TRPV4 ~6 
Warm (27–34˚C), osmotic cell 
swelling, 5’6’-EET, anandamide, 
4αPDD, exocytosis 
Osmosensor, warm 
sensor (27°C) in 
keratinocytes 
Altered body osmolarity; increased bone 
mass; impaired bladder function; reduced 
inflammatory hyperalgesia 
TRPV5 >100 
Constitutively active1, exocytosis 
(?) 
Ca2+ reabsorption in 
kidneys 
Impaired renal Ca2+ reabsorption; 
decreased bone thickness 
TRPV6 >100 
Constitutively active1, store 
depletion (?), exocytosis (?) 
Ca2+ - homeostasis, 
differentiation 
keratinocytes 
Impaired epididymal Ca2+  absorption, male 
hypofertility, impaired Ca2+  absorption 
TRPM1 <1 Translocation (?) Visual perception? impaired ON bipolar cell function and vision 
TRPM2 ~0.3-2 
ADP-ribose, cADP-ribose, 
pyrimidine 
Redox sensor 
Impaired neutrophilin filtration in 
inflammation, increased ROS production in 
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nucleotides, arachidonic acid, 
NAD, H2O2, Ca2+ 
phagocytes, higher basal glucose level and 
impaired glucose tolerance 
TRPM3 ~1-10 (2) 
Constitutively active1, osmotic 
cells welling, store depletion (?), 
pregnenolone sulfate, d-erythro-
sphingosine (?),  heat (33-40°C) 
Insulin secretion 
Pain sensation 
Impaired noxious heat perception 
TRPM4 
Monovalent 
selective 
Ca2+, voltage modulated, PIP2 
Allergy, immune 
response 
 
Increased release of inflammatory 
mediators from mast cell and cutaneous 
anaphylaxis; impaired dendritic cell 
migration; reduced secondary hemorrhage 
and lesions after spinal cord injury, 
hypertension associated with increased 
catecholamine release from chromaffin 
cells 
TRPM5 
Monovalent 
selective 
Taste receptor activation 
(T1R,T2R), Ca2+, Voltage 
modulated, PIP2,  heat (15–35˚C) 
Taste 
Impaired sweet, umami, and bitter taste 
reception; deflects in glucose-induced 
insulin release 
TRPM6 <10(3) Mg2+ inhibited, translocation 
hypomagnesemia, 
hypocalcemia 
Embryonic lethality, neural tube defects in 
development 
TRPM7 ~0.2-2(3) 
Activation mode of native 
channels unclear, Mg2+ inhibited, 
ATP, protons, phosphorylation, 
PIP2 
Cell viability 
Embryonic lethality; conditional TRPM7 
deletion in T cells causes abnormal 
thymocyte development 
TRPM8 ~0.3-4 
Cool (23–28˚C), menthol, icilin, 
pH modulated, PIP2 
Cool temperature 
sensor (23°–28°C) 
Deficiencies in response to cold 
TRPA1 ~0.8-5 
Cold (17˚C) (?), icilin, 
isothiocyanates, allicin (garlic), 
cannabinoids, bradykinin, PLC 
activation, DAG, PUFAs 
Cold pain sensor 
(17°C), hearing 
Reduced response to noxious cold and 
intestine mechanical force 
TRPML1 (4) 
Activation mode of native 
channels unclear, potentiation by 
low pH 
Lysosomal trafficking?, 
mucolipidosis type IV 
Motor deficits, retinal degeneration, 
decreased life span 
TRPML2 (4) 
Activation mode of native 
channels unclear, potentiation by 
low pH 
- - 
TRPML3 (5) 
Activation mode of native 
channels unclear, removal and 
readdition of extracellular Na+ 
Hearing 
Varitint-waddler (Va) mice with a TRPML3 
(A419P) gain of function mutation exhibit 
deafness, circling behavior, and 
pigmentation defects 
TRPP2 
Non-
selective 
Translocation with TRPP1, fluid 
flow, mechanical gating (?) 
Polycystic kidney 
disease 
Lethal E13; embryonic cysts and extrarenal 
abnormalities including left-right asymmetry 
of visceral organs 
TRPP3 ~1-10 Ca2+, voltage modulated - - 
TRPP5 
Non-
selective 
? - - 
(1) Not yet measured in primary cells; (2 )significant differences in individual splice variants; (3 )divalent cation selective (Ca2+ and 
Mg2+); (4) localization primarily intracellularly in endolysosomes, permeability for Na+, K+, Ca2+, Fe2+; (5) localization primarily 
intracellularly in endolysosomes, permeability fo Na+, Ca2+, K+. 
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2.4 Transient receptor potential Melastatin 3 (TRPM3) 
TRPM3 is the last identified member of the TRPM subfamily [101-104]. TRPM3 is most 
closely related to TRPM1, the founding member of the subfamily. It differs from TRPM2, 
TRPM6 and TRPM7 by the lack of enzymatic activity and from TRPM4 and TRPM5 by its 
permeability for Ca2+ ions. Similar to TRPM8, TRPM3 is activated by changes of temperature 
[105]. 
2.4.1 The Trpm3 gene encodes a variety of different TRPM3 proteins 
Trpm3 genes display a highly conserved configuration in mouse, rat and human. In the 
mouse, the gene is located on the chromosome 19b spanning more than 850 kb and 
comprising 28 exons (Figure  2-7). The human and rat genes are located on chromosome 9 
(9q21.11-q21.12) and chromosome 1q5, respectively [106]. Trpm3 genes encode a large 
number of variants due to alternative splicing of their primary transcript (Figure  2-7). 
Furthermore, the variability of TRPM3 transcripts is increased by the presence of at least 
three promoters that give rise to three alternative transcription start sites encoding three 
different amino termini of the protein. The different promoters were supposed to regulate the 
expression of different protein isoforms called TRPM3α (α1 to α5) starting within exon 1 and 
lacking exon 2, TRPM3β (β1 to β17) starting within exon 2 and finally isoforms starting with a 
ATG codon located at the very end of exon 4 ([106], Figure  2-7). 
The splicing events affect exons 8, 13, 15, 17, 20, 24 and 28 and hitherto at least 24 different 
TRPM3 variants have been described from one species (Figure  2-7). However, only by 
splicing at least 27 = 128 isoforms may exist (Figure  2-7). The splicing pattern of these exons 
is highly conserved in human, rat and mouse transcripts indicating important functions of the 
related protein modifications. For example, mTRPM3α2 proteins differ from mTRPM3α1 
proteins by the absence of 12 amino acid residues in the pore forming region of the channel 
and display high permeability for Ca2+ in contrast to mTRPM3α1 [103].  
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Figure  2-7: The Trpm3 gene, its transcripts and the encoded proteins, adapted from [106].  
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A. Genomic organization of the mouse Trpm3 gene on chromosome 19. Predicted transcription start 
sites are indicated by arrows. A microRNA sequence (miR-204) is located in intron 8. Exon 19 which 
was subject of the targeting strategy to obtain a TRPM3-deficient mouse line [105,107] is highlighted 
in red.  B. Structure of Trpm3 transcripts identified in mouse tissues. Their reading frames are flanked 
by stop codons establishing entire protein coding sequences with GenBank accession numbers as 
indicated. The coding parts of the transcripts are shown as grey bar, the noncoding parts as thin line. 
The upper bar indicates the relative size of the protein coding exons 1 - 28 with spliced parts 
highlighted in blue. Start codons (ATG) present in exons 1, 2 and 4 and stop codons (stop) in exon 28 
are indicated.  C. Schematic presentation of TRPM3 protein isoforms (black bars) scaled to their 
relative size with protein identifiers and numbers of amino acid residues (aa) indicated in brackets. 
Internal protein domains removed by alternative splicing are indicated as thin lines. The organization 
of domains of TRPM3 proteins is shown above, with calmodulin/S100 protein interacting regions 
(CamBS/S100), ICF region, transmembrane region including the six transmembrane domains (white 
rectangles), the channel pore (P), the TRP motif (TRP) and a coiled-coil region (cc) as indicated. 
TRPM3 proteins are known to interact with theirselves and with other TRP channels to form 
homo- and hetero-multimeric channels. It has been shown by immunoprecipitation that 
TRPM3α1 variants interact with TRPM3α2 and with TRPM1 [108]. This interaction was also 
confirmed by intermolecular fluorescence resonance energy transfer (iFRET) of TRPM3 
proteins fused to the fluorescent proteins CFP or YFP [109,110]. The introduction of 
TRPM3α1 or TRPM1 into TRPM3α2 overexpressing HEK293 cells revealed a dominant-
negative effect on the TRPM3α2-dependent Ca2+ entry confirming a direct molecular 
interaction of TRPM3 and TRPM1 proteins [108]. Recently, a region that is indispensable for 
TRPM3 channel function (ICF) has been identified [111]. The ICF domain consists of 10 
amino acid residues encoded by the last part of exon 13 and interestingly, is also subject of 
alternative splicing. The ICF region is conserved throughout the TRPM subfamily and was 
suggested to be essential for the function and the formation of operative TRPM channels. 
TRPM3 variants lacking the ICF domain (∆ICF) showed reduced interaction with other 
TRPM3 isoforms and a diminished occurrence in the plasma membrane. Furthermore, 
coexpression of ∆ICF-proteins with functional TRPM3 subunits resulted in impaired TRPM3-
mediated Ca2+ entry and reduced the number of channels indicating that the ICF region is 
necessary for the function and trafficking of TRPM3 proteins [111]. 
TRPM3 channel activity is suggested to be regulated by the calcium binding protein 
calmodulin (CaM) since the comparison of TRPM3 amino acid sequence with calmodulin-
binding proteins indicated the presence of six putative calmodulin binding sites within the N-
terminus of TRPM3 [112]. Recently, the presence of two of these binding sites was 
confirmed experimentally [113]. Interestingly, these two binding site were found to bind both 
calmodulin and another calcium binding protein (S100A) in calcium-dependent manner. 
These two proteins are able to compete for the same binding sites within the TRPM3 N-
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terminus [113]. PIP2 was also found to interact with the CaM/S100A binding sites, implying 
an important role of this region in the regulation of TRPM3 channel activity [114]. 
2.4.2 Expression and function of TRPM3 proteins 
The expression pattern of TRPM3 in different tissues was uncovered by the use of a variety 
of molecular and biochemical techniques like RT-PCR, in-situ hybridization, 
immunohistochemistry as well as Northern- and Western blot analysis (Table  2-2).  RT-qPCR 
analysis of human and mouse tissues revealed strongest expression of TRPM3 in the brain, 
pituitary gland, kidney and adipose tissues. For neuronal TRPM3 channels, their occurrence 
in dorsal root ganglia (DRG) and their function as sensor of noxious heat is well established 
[105]. However, in the central nervous system the Trpm3 gene is expressed not only in 
neurons but also in epithelia and oligodendrocytes, where TRPM3 channels have been 
proposed to participate in differentiation and CNS myelination [110]. In mouse brain, 
transcripts could be detected in several regions (Table  2-2) with most prominent expression 
in epithelial cells of the choroid plexus [103]. However, as shown in Table  2-2, TRPM3 is 
expressed in quite a number of other tissues and cell types with hitherto unknown functions.  
In isolated pancreatic β-cells, PregS induced TRPM3-mediated Ca2+ influx resulting in an 
enhanced insulin secretion of these cells (Table  2-1, [115]). This and other studies [116] 
suggested the importance of TRPM3 signaling in the regulation of insulin synthesis and 
secretion [117]. Furthermore, TRPM3 proteins contribute to pain sensation in dorsal root 
ganglia (DRG). TRPM3-deficient mice showed an impaired perception of noxious heat [105] 
and TRPM3 antagonists like Hesperetin and isosakuranetin reduced the nocifensive 
behavior after PregS injection [118].  TRPM3-dificient mice also showed reduced consensual 
pupillary responses to light suggesting that TRPM3 might play an indirect role in these 
responses [107]. Furthermore, TRPM3 signaling has been suggested to be coupled to aortic 
contraction and suppression of proinflammatory interleukin-6 secretion in vascular smooth 
muscle cells from human and mouse [119]. Since TRPM3 is expressed in the brain with a 
prominent expression in choroid plexus epithelial cells (CPECs), it was hypothesized that 
TRPM3 might be involved in the production of the cerebrospinal fluid and the regulation of its 
ionic composition [103,120]. According to TRPM3 expression in the kidney and its activation 
by hypotonicity, it has been suggested that TRPM3 plays a role in renal osmohomeostasis 
[102,121].   
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Table  2-2: TRPM3 expressing tissues and the methods of their detection (adopted from [106]) 
Method of detection* 
Tissue/cell 
type 
RT-PCR RT-
qPCR 
Micro-
array 
Northern ISH Western IHC/
ICC 
cDNA 
library 
Transgene Function 
Nervous system 
total brain [101,102, 
110,115, 
122-124] 
[122,123] 
[63,102]  [101-
103,125] 
 [110,115]     
cerebrum  [126]     [110]    
brainstem       [110]    
locus 
coeruleus 
 [102]         
spinal cord  [102]         
hippocamp
us 
 [126]     [110]    
forebrain  [126]         
corpus 
callosum 
      [110]    
chor. 
plexus 
epithel  
 [102]  [103] [103, 
127-
129] 
     
tenia tecta     [103]      
ILSN#     [103]      
hypothalam
us 
 [102]         
cerebellum    [102,126]     [110,
130] 
   
purkinje 
cell 
      [130]   [130] 
 
oligodendro
cyte 
[110]      [110]    
Oli-
neu/OLN-
93cell 
     [110]    [110] 
basal 
ganglia/ 
substantia 
nigra 
 [102,126]         
dorsal root 
ganglion 
[124] [105,124,
131,132] 
  [105] [105]    [105,118, 
133] 
trigeminal 
ganglion 
[134] [105,124]   [105] [105]    [105] 
nodose 
ganglion 
 [131]         
SH-SY5           
Sensory system 
eye  (total)   [107] [103] [128]      
retina [125] [135,136]  [125] [125,128,
129] 
  [137] [107]  
iris        [138]   
lens  [139]   [128,129,
140] 
     
retinal pig. 
epithel. 
 [141,142]   [125,128,
140] 
  [137]   
Muller cell [107]        [107]  
ciliary body     [125,128,
140] 
   [107]  
inner ear [143,144]       [144]   
Cardiovascular system 
heart [124] [145]         
pulmonary 
artery  
[122,146] [146,147]         
coronary 
artery 
[123]          
mesenteric 
artery 
[123]          
femoral 
artery 
      [119]    
aorta  [119,123, 
146] 
[146]        [119] 
saphenous [119] [119]     [119]   [119] 
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vein 
Endocrine system 
pituitary 
gland 
 [63]  [108]       
pancreas 
(total) 
[101,115]     [115]    [115] 
pancretic 
islet cell 
[148]         [149] 
INS1 [115,148] [150]  [115]  [115,116,
151] 
   [115,149, 
151] 
Urinary system 
kidney 
(total) 
[101,124] [63,102]  [101,102]  [101]     
collect. tub. 
epithel. 
    [102]      
MDCKII 
cell 
[152]          
ccRCC§  [153]         
Reproductive system 
ovary [101]          
testis [124] [102,124]  [102]       
sperm cell [154]          
prostate [155] [155]         
Other tissues/cells 
MG-63 cell [156]          
SaOS cell [156]          
U2 OS cell [156]          
odontoblast [157]          
adipose 
tissue 
 [63]         
buccal 
mucosa 
 [158]         
synoviocyte [159]      [159]   [159] 
glioma  [160]         
* References demonstrating expression of TRPM3 as indicated by numbers, #intermediate lateral septal nuclei, §clear cell renal cell 
carcinoma 
2.4.3 Pharmacology of TRPM3 channels 
Depending on the isoform, the activation mechanisms of TRPM3, the selectivity and the 
conductance of the channels turned out to be different. For example, the long variant of 
human TRPM3 has been suggested to be activated by store depletion [102], whereas the 
short variant hTRPM31325 mediates Ca2+ entry upon extracellular application of hypotonic 
solutions [101]. Furthermore, mouse TRPM3α1 channels are permeable for monovalent 
cations, whereas mouse TRPM3α2 channels allow the entry of divalent cation such as Ca2+ 
and Mg2+ [103]. Human TRPM31325 was reported to be the first cation channel activated by D-
erythrosphingosine [161] but TRPM3 channels have been also described as steroid-
receptors channels, since pregnenolone sulfate (PregS) is the most potent agonist of TRPM3 
[115]. At body temperature of 37°C, TRPM3 is activated by ~ 100 nM PregS, which is close 
to serum concentrations that have been reported to be 130 and 140 nM in female and male, 
respectively [162,163]. However, at room temperature 100 µM PregS are needed to fully 
activate the channel [115]. TRPM3 channels were also shown to be activated by nifedipine 
which is well-known as a blocker of voltage-gated calcium channel (VGCC, [115]). It has 
been shown that nifedipine and PregS are able to activate TRPM3 synergistically and that 
they act at different binding sites [164]. Recently, an alternative permeation pathway through 
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TRPM3 channels has been described. This pathway is activated by the combined application 
of neurosteroids and clotrimazole or other structurally related drugs and is still active after 
desensitization or blockade of the central pore. Activation of this pathway leads to massive 
Na+ influx, enhanced excitation of sensory neurons and in turn increased TRPM3 dependent 
pain intensity [163]. 
Similar to other TRP channels, TRPM3 channel activity was described to be inhibited by the 
extracellular application of 100 μM 2-aminoethoxydiphenyl borate (2-APB, [165]). 
Furthermore, 100 μM concentration of trivalent ions such as Gd3+ and La3+ also inhibit Ca2+ 
influx through TRPM3 channels [101,102]. The nonsteroidal anti-inflammatory drug 
mefenamic acid [151], antidiabetic PPARγ-agonists such as rosiglitazone, troglitazone, and 
pioglitazone [166] and cholesterol [119] have been shown to decrease TRPM3 channel 
activity. Finally, progesterone was shown to reduce TRPM3 activity in vascular smooth 
muscle cells [167]. However, none of the above mentioned substances are specific for 
TRPM3 as they also block a plethora of other channels. By screening a library of natural 
compounds, novel potent TRPM3 blockers have been discovered recently including 
ononetin, naringenin and Hesperetin [168]. Ononetin is a deoxybenzoin from Ononis spinosa 
while naringenin and Hesperetin belong to citrus fruit flavanones. In a following study, further 
TRPM3 channel blockers like liquiritigenin and isosakuranetin were identified and 
isosakuranetin was defined as the most potent inhibitor of TRPM3 channels with an IC50 of 
50 nM [118].  
2.5 Aim of the work 
The aim of this work was the identification of TRPM3 channels in the pituitary gland and the 
determination of their function(s) in defined cell populations.  
To accomplish this goal: 
1. I constructed and screened a pituitary cDNA library and analyzed the number and 
identity of different TRPM3 isoforms. 
2. I used mono- and polyclonal anti-TRPM3 antibodies as well as a transgenic mouse 
line expressing the GFP-reporter protein under the control of TRPM3 promoter to 
identify TRPM3 expressing cells. 
3. I analyzed the functional properties of TRPM3 channels and their physiological roles 
in the identified cell populations using TRPM3 specific ligands and cells from wild 
type and TRPM3-deficient mice.  
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3 Materials 
3.1 Chemicals 
Unless otherwise indicated, chemicals used for this work were purchased from one of the 
following suppliers: Sigma-Aldrich, Invitrogen, Merck, Applichem, VWR, Biochrome or Roth. 
3.2 Reagent systems (Kits) 
Agilent RNA 6000 Nano Kit® 
Alpha-MSH ELISA Kit (MyBioSource) 
GeneEluteTM HP Plasmid Miniprep Kit (Sigma-Aldrich) 
peqGOLD RNAPure TM (Peqlab Bio technology, Erlangen) 
Phusion® High-Fidelity PCR Kit (New England Biolabs) 
Milliplex MAP® Kit, Rat/Mouse Neuropeptide (Merck Millipore) 
SuperScript®  One-Step RT-PCR with Platinum® Taq DNA Polymerase (Invitrogen) 
SuperScriptTM First-Strand Synthesis System for RT-PCR (Invitrogen) 
Thermo Scientific™ Pierce™ BCA™ Protein Assay  
Western LightningTM Plus ECL (Perkin Elmer) 
3.3 Vectors 
pUC 19 
The cloning vector pUC19 (Figure  3-1) comprises a fragment carrying the sequences for the 
α-peptide of the lacZ gene and the multiple cloning site (MCS), in addition to portions of 
pBR322 and M13mp19 (Figure  3-1). The pBR322 fragment carries the ampicillin resistance 
gene and the origin of replication. The region of M13 mp19 vector is responsible for the 
single strand production. Insertion of cloned fragments into the MCS disrupts the reading 
frame of the α-peptide and gives rise to white-colored colonies on X-Gal / IPTG containing 
solid media.  
pCAGGSM2-IRESGFP 
The expression vector pCAGGSM2 IRESGFP [169] comprises 6153 bp and is based on the 
plasmid pCAGGS (Figure  3-1, [170]). The expression of the target cDNA is under the control 
of a chicken β-actin promoter. An internal ribosome entry site (IRES) located downstream of 
the multiple cloning site allows the simultaneous expression of the target cDNA and the 
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cDNA encoding the green fluorescent protein (GFP). This way the expression of the target 
cDNA can be visualized by the fluorescence of GFP. 
 
Figure  3-1: Circular map of the vectors used. 
Shown are: the origin of replication derived from the ColE1 Plasmid (ColE1 ori) and the simian virus 
SV40 (SV40 Ori); the multiple cloning site (MCS); binding sites of the primers FV79, FV80, 
pCAGGSfor and PH127; the enchancer sequence from the cytomegalovirus (CMV IE); the promotor of 
the β-actin gene from chicken (P β-actin); the polyadenylation sequence of the rabbit β-globin gene 
(rabßglobin pA); the internal ribosome entry site (IRES); coding sequences for β-lactamase (AmpR); 
the sequence encoding the α-peptide of the β-galactosidase (lacZ) and the green fluorescent protein 
(EGFP), recognition sequences of the restriction endonucleases SmaI and EcoRI.  
3.4 Oligonucleotides 
Oligodeoxyribonucleotide primers (Table  3-1) were purchased in lyophilized form from 
Eurofins MWG Operon (Ebersberg) and dissolved in sterile H2O in a concentration of 100 
pmol/µl. Stock solutions were stored at -20 °C. 
Table  3-1: Oligonucleotide primers used for sequencing  
Primer name Primer sequence (5’→3’) Origin of the sequence 
FV 79 CACGACGTTGTAAAACGAC pUC19 
FV 80 CAGGAAACAGCTATGAC pUC19 
PH 389 CCAACTGAGCTTAGCTTTAGCC Mouse TRPM3 cDNA 
PH 401 CTACATTGTTCGCCAGAGCAG Mouse TRPM3 cDNA 
PH 422 CCCTCTAGAGCTGGAGTGAAATGTGCTTTTCC Mouse TRPM3 cDNA 
PH 427 GCCCTTAAGTTGAGGAGAGGACGGAAGACA Mouse TRPM3 cDNA 
PH 520 AGGATCATCCAAGTCGATGTCC Mouse TRPM3 cDNA 
Nucleotides which are non-homologous to the indicated sequence are underlined. 
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Table  3-2: Oligonucleotide primers used for RT-PCR 
Primer name Primer sequence (5’→3’) Origin of the sequence 
PH 382 GAGAGCTGAGCGCAGGCTG Mouse TRPM3 cDNA 
PH 383 GAATGGGCAAGAAGTGGAGGG Mouse TRPM3 cDNA 
PH 384 AATGTGTTCACATCATACCGAGC Mouse TRPM3 cDNA 
PH 385 TCCTGCAACACACGGTAAGCC Mouse TRPM3 cDNA 
PH 386 GGTTGTGGAAGGTGCTAGAGC Mouse TRPM3 cDNA 
PH 423 GCCCTTAGGAGCAAGCTCACCGTTCTCAATAG Mouse TRPM3 cDNA 
PH 429 AAGAAGGTTCAGGGGCTCAGG Mouse TRPM3 cDNA 
PH 520 AGGATCATCCAAGTCGATGTCC Mouse TRPM3 cDNA 
PH 521 CCCAATGAGGAGCCATCTTGG Mouse TRPM3 cDNA 
PH 522 CGGGTCTCATTCTGTCCACAG Mouse TRPM3 cDNA 
PH 561 GGTACCTAACAATGTCAGGGAC Mouse TRPM3 cDNA 
PH 562 AAGTAGGGAGAAGTTGGTCACC Mouse TRPM3 cDNA 
PH 777 TGGTGGTGCTGATGAGCTTTGG Mouse TRPM3 cDNA 
PH 778 TGGATTGTCTTGCCATCCTCTCG Mouse TRPM3 cDNA 
C5-139 CGCACACCGGCCTTATTCC IRES-GFP 
 
Table  3-3: Oligonucleotide primers used for amplification of TRPM fragments from GLAST 
positive and GLAST negative cells from mouse intermediate and posterior pituitary lobe 
Primer name Primer sequence (5’→3’) Origin of the sequence 
PH 773a GCGACGAAGGAGGAGTCATAAACG Mouse TRPM1 cDNA 
PH 774a CATCTTGCTGACCCTCGGAACC Mouse TRPM1 cDNA 
PH 775 GAAAGTGGGGAAGTATGTCCGGG Mouse TRPM2 cDNA 
PH 776 TTGAGCCACCTTGACCAAGCC Mouse TRPM2 cDNA 
PH 779 AGGTCCTCCTGGGACTGTAGAACCC Mouse TRPM4 cDNA 
PH 780 GCAACACGTGGGCAAACAGC Mouse TRPM4 cDNA 
PH 781 TCAAGGCACTTGTGAAAGCCTGC Mouse TRPM5 cDNA 
PH 782 TCACGAGGGCATCTGTCATCACC Mouse TRPM5 cDNA 
PH 783 CAGCCCTACAAATCCAAGGAGAAGC Mouse TRPM6 cDNA 
PH 784 TGCCTCTTCATGAGCACCGC Mouse TRPM6 cDNA 
PH 785 CATTCGGGATGTCAAGCAGGG Mouse TRPM7 cDNA 
PH 786 CGACCTGACCTCCGGTTATTTCC Mouse TRPM7 cDNA 
PH 787 TGCGCTGTACAAAGCCTTCAGC Mouse TRPM8 cDNA 
PH 788 TGGGTCTGTCCTTTATGAGAGCCG Mouse TRPM8 cDNA 
PH 928 TGGTGAGAAAACGGTGCATGCTTA Mouse TRPM3 cDNA 
PH 930 TCTGTCCAGGACTAGGGCATCCAG Mouse TRPM3 cDNA 
 
3.5 Primary and secondary antibodies 
Antibodies used for immunostaining and western blots are listed in the following tables. 
Table  3-4: Antibodies used for immunostaining 
Antibody Host and concentrations Dilution used Origin 
Anti-LH Rabbit polyclonal, 0.1 mg/ml 1:5000 NHPP*   
Anti-FSH Rabbit polyclonal, 0.1 mg/ml 1:20000 NHPP* 
Anti-ACTH Rabbit polyclonal, 0.1 mg/ml 1:20000 NHPP* 
Anti-TSH Rabbit polyclonal, 0.1 mg/ml 1:5000 NHPP* 
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Anti-GH Rabbit polyclonal, 1.5 mg/ml 1:20000 NHPP* 
Anti-PRL Rabbit polyclonal, 1 mg/ml 1:20000 NHPP* 
Anti-LH Guinea pig 1:5000 NIDDK** 
Anti-PRL Guinea pig 1:12000 NIDDK** 
Anti-α MSH Rabbit polyclonal, 0.1 mg/ml 1:2000 abcam 
Anti-GFP Rabbit polyclonal, 2 mg/ml 1:5000 Invitrogen 
Anti-GFP Goat monoclonal, 1 mg/ml 1:1000 Rockland 
Anti-GLAST (PE) Mouse monoclonal,100 µg/ml 1:20 Miltenyi Biotec MACS  
Anti-GFAP Rabbit polyclonal, 2.9 mg/ml 1:500 Dako 
Anti-GFAP Alexa Fluor 488 Mouse monoclonal,100 µg/ml 1:50 Cell Signaling 
Anti-Neurophysin I Goat polyclonal, 200 µg/ml 1:1500 Santa Cruz 
Anti-Neurophysin II Goat polyclonal, 200 µg/ml 1:1500 Santa Cruz 
Anti-Synapsin I Goat polyclonal, 200 µg/ml 1:1500 Santa Cruz 
Anti-S100B Rabbit polyclonal, 2 mg/ml 1:500 Abcam 
Anti TRPM3 (AK695) Rabbit polyclonal, 1 mg/ml 1:1000 Lab-made 
Anti TRPM3 (9F6) Rat monoclonal, 1 mg/ml 1:200 Lab-made 
Anti-rabbit Alexa Fluor 488 Donkey, 2 mg/ml 1:1000 Invitrogen 
Anti-goat Alexa Fluor 488 Donkey, 2 mg/ml 1:1000 Invitrogen 
Anti- guinea pig Cy 3 Donkey, 2 mg/ml 1:1000 Jackson Labs 
Anti-rabbit Alexa Fluor 488 Goat, 2 mg/ml 1:1000 Invitrogen 
Anti-rabbit Alexa Fluor 594 Goat, 2 mg/ml 1:1000 Invitrogen 
Anti-rabbit Alexa Fluor 594 Donkey, 2 mg/ml 1:1000 Invitrogen 
Anti-goat Alexa Fluor 546 Donkey, 2 mg/ml 1:1000 Invitrogen 
Anti-goat Alexa Fluor 594 Donkey, 2 mg/ml 1:1000 Invitrogen 
Anti-rat  Alexa Fluor 594 Goat, 2 mg/ml 1:1000 Invitrogen 
Anti-rat  Alexa Fluor 488 Goat, 2 mg/ml 1:1000 Invitrogen 
* NHPP = National Hormone & Peptide Program, Harbor-UCLA Medical Center, 1000 W. Carson St., Torrance, 
California 90509, U.S.A, Dr. A. F. Parlow, Scientific Director. 
** NIDDK = National Institute of Diabetes and Digestive and Kidney Diseases; Maryland, USA. 
Table  3-5: Antibodies used for Western blots 
Antibody Antigen Host Dilution used Origin 
AK695 mTRPM3-
peptidsequence 
QEKEPEEPEKPTKEK 
Rabbit polyclonal 1:200 Lab-made; 
1 mg/ml 
9F6 mTRPM3α, epitope 
ERAESNKIRSRTS 
Rat monoclonal 1:200 Lab-made; 
1 mg/ml 
Anti-GFP GFP Mouse monoclonal 1:500 Roche;  
0,4 mg/ml 
Anti-Na+/K+ 
ATPase 
Na+/K+ ATPase    
Anti-rabbit 
Horseradish 
peroxidase 
(HRP)-linked  
rabbit IgG Donkey polyclonal 1:50000 GE Healthcare 
Anti-Mouse HRP 
-linked 
mouse IgG Goat 1:50000 Dianova;  
0,8 mg/ml 
Anti-Rat HRP -
linked 
rat IgG Rabbit polyclonal 1:40000 Sigma;  
8,3 mg/ml 
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3.6 Bacterial strains 
In this work the E. coli strain XL1-Blue was used for the cloning of plasmid DNA [171]. This 
strain is derived from E. coli K12 and has the following genotype: supE44, hsdR17, recA1, 
endA1, gyrA46thi, relA1, lac-, F'[proAB+lacqZΔM15 Tn10 (tetr)]. 
3.7 Mice 
All animal experiments mentioned in this work were approved in accordance with the 
Saarland University Ethic Regulations and the animal welfare committees of Saarland’s 
State. In this work, a mouse line lacking part of the Trpm3 gene (TRPM3-knockout, KO) was 
used. Additionally, a mouse line carrying the GFP-cDNA in the Trpm3 locus  (TRPM3-GFP-
knock in, short GFP-Ki) was used as reporter strain of TRPM3 expression [108]. The strategy 
used to generate these mouse lines is explained in Figure  3-2. For the all experiments, both 
male and female mice were used at an age of 2-6 months. TRPM3-GFP-Ki mice (short GFP-
Ki) had a mixed 129SvJ/C57Bl6/N genetic background. For this line, mice of the F1 
generation from 129SvJ and C57Bl6/N intercrosses were used as wild type controls. 
TRPM3-deficient mice were back-crossed for at least 10 generations to the C57Bl6/N mouse 
line which also served as wild type controls. All mice were bred and kept in a specific 
pathogen free facility (SPF). They were maintained in a 12 hour light-dark cycle, and water 
and standard food was available ad libitum. At the end of each experiment, a biopsy from the 
tip of the tail was taken to confirm the genotype of each mouse.  
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Figure  3-2: TRPM3 targeting strategy [108].  
The genomic structure of the TRPM3 gene including the pore coding exon 24 (P) is shown and a 
higher magnification of this region is indicated below. The targeting construct included two flanking 
thymidine kinase cassette (TK), the 5`-homology with the floxed exon 24, the 3`-homology, the splice 
acceptor (SA), the IRES-GFP cassette and the polyadenylation site (PA). The location of the loxP 
(orange triangles) and FRT (yellow triangles) sequences is also indicated. A L3F2 allele (carrying 
three loxP and two FRT) was generated by the homologous recombination of the targeting construct 
with the wild-type allele. L1 allele (KO), L2F2 allele (conditional KO) and L2 allele (WT) were 
generated by the activity of Cre-recombinase. The L3F1 allele (GFP-Ki) and the L2F1 allele were 
generated by the activity of Flp-recombinase. 
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4 Methods 
4.1 Molecular biological methods 
4.1.1 Cultivation and transformation of eukaryotic cells 
4.1.1.1 Cultivation of HEK 293 cells 
Human Embryonic Kidney (HEK) 293 cells were cultured at 37°C in a humidified atmosphere 
containing 5 % CO2 either in 75 cm² culture flasks with 10 - 15 ml of medium or cultured in 
culture dishes (∅ 3 cm) with 2 ml of medium, to passage into an appropriate culture vessel, 
the cells were washed once with PBS, trypsinized with 30 – 40 μl trypsin-EDTA/cm² surface 
area, diluted 1:2 up to 1:10 with fresh medium and transferred.  
Culture medium 
Minimum essential medium (# 31095-029, Invitrogen)  
10% Fetal calf serum  (# 104370-028, Invitrogen) 
4.1.1.2 Preparation and cultivation of primary pituitary cells 
A mouse was killed by cervical dislocation and the head was decapitated. The cover of the 
skull was cut using a small bone scissor and the brain was removed using spatula. The 
pituitary gland was directly isolated and placed in cold dispersion medium I and cut into 8-
10 pieces. In some cases the posterior/intermediate lobe were dissected from the anterior 
lobe. The pieces were digested for 30 min at 37°C in sterile filtered, freshly prepared 3 mg 
collagenase (CLS type II, Biochrom)/ ml dispersion medium I. During the incubation time, the 
pieces were triturated several times by pipetting through 1000 and 200 µl pipette tips. 
Thereafter, the cells were collected by centrifugation at 800 rpm (Hettich, Rotana) for 5 min 
and resuspended in 125 µl dispersion medium II. 25 µl of the cell suspension were plated 
onto poly-L-lysine covered coverslips and incubated at 37°C, 5 % CO2 for 1 h before 1.5 ml 
of the culture medium were added. 
Dispersion medium I  
1x  HBSS (Invitrogen, 14025) 
5 mg/ml BSA  
10 mM  HEPES  
10 mM  glucose  
pH was adjusted to 7.3 - 7.4 with 2 mM NaOH 
Dispersion medium II   
1x  DMEM (Invitrogen, 41966 with Nateruimpyruvate) 
5 mg/ml  BSA 
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Culture medium   
1x  DMEM (Invitrogen, 41966 with Nateruimpyruvate) 
10000 u/ml  Penicillin 
10 mg/ml  Streptomycin 
10 %  FCS  
Primary “explant” cultures were prepared as described [172]. In brief, a piece of the posterior 
lobe (separated from the intermediate lobe) was placed onto collagen-covered coverslips, 
covered with culture medium and incubated at 37°C, 5 % CO2. The medium was exchanged 
every two days. 
4.1.1.3 Transformation of eukaryotic cells 
Cells were plated one day prior to transfection at a cell density of 60 – 70 % in culture dishes 
(∅ 3 cm). HEK293 cells were transfected with FuGene6 reagent according to the instructions 
of the manufacturer (Roche, Mannheim). Highest transfection rates were achieved with 6 μl 
transfection reagent and 2 μg DNA or with 3 μl transfection reagent and 1 μg DNA. 
Transfected cells were used for experiment after 24 - 48 h. 
4.1.2 Cultivation and transformation of Escherichia coli 
4.1.2.1 Cultivation of Escherichia coli 
The bacteria were grown in liquid LB medium or on LB Agar plates under aerobic conditions 
at 37°C. For the preparation of LB Agar plates LB medium was supplemented with 15 g/l of 
agar autoclaved and cooled to 50°C and poured into sterile petri dishes (∅ 10 cm). Selective 
medium was prepared by adding 50 g/ml ampicillin at 50°C.  
LB medium (pH 7.5)  
1 % (w/v) Tryptone / Peptone  
0.5 % (w/v) Yeast extract  
1 % (w/v) NaCl 
4.1.2.2 Preparation of electrocompetent E. coli cells 
To prepare electrocompetent E. coli cells, 2 x 500 ml LB medium in 2 l/ Erlenmeyer flasks 
were inoculated with 5 ml of an overnight culture of the E. coli strain XL-1 blue. The cells 
were incubated at 37°C and were shaked at 225 rpm until the optical density of the culture 
reached 0.6 at a wavelength of λ = 578 nm. The cell suspension was transferred into four 
sterile JA-10 centrifuge beakers (Beckman) and incubated on ice for 30 min. The cells were 
harvested by centrifugation at 4420 g at 4°C for 15 min. To remove the rest of the medium 
and salts, the cells were washed two times with ice-cold sterile water and one time with 
sterile and ice-cold 10 % (v/v) glycerol. Finally, the cells were resuspended in a total volume 
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of 1.5 ml 10 % glycerol. Aliquots of 60 µl were frozen immediately in dry ice/ EtOH and stored 
at -80°C. The competence of the cells was tested by transformation of 10 ng of the plasmid 
pUC 18.  
4.1.2.3 Transformation of plasmid DNA into electrocompetent bacterial cells 
An aliquot of electrocompetent cells ( 4.1.2.2) was thawed on ice and 40 µl of cells were 
mixed with the 2 µl of DNA. To remove salts prior to transformation, ligation reactions were 
precipitated with ammonium acetate / ethanol and precipitated the DNA was dissolved in 2 µl 
H2O. The DNA / cells mixture was transferred into a pre-cooled electroporation cuvette with 
1 mm electrode gap (peqlab). The electrical pulse was performed using a Gene-Pulser (Bio-
Rad) at a capacitance of 25 µF, a voltage of 2.5 KV and a resistance of 100 Ω. The time 
constant of the electrical pulse was always close to 2.5. 1 ml of LB medium supplied with 
50 mM magnesium sulfate, 50 mM magnesium chloride and 2 % glucose was added 
immediately after performing the pulse. The cell suspension was shaked at 37°C and 
200 rpm for 1 h, plated onto solid LB medium supplied with ampicillin and incubated 
overnight at 37°C. Cells of the E. coli strain XL1-Blue carry the ΔM15 deletion of the lacZ 
gene and are therefore not capable to form a functional β-galactosidase [171]. The α-peptide 
of the β-galactosidase, encoded by plasmids like pUC18 and pUC19 can complement this 
deficiency after transformation (α-complementation). A functional ß-galactosidase can be 
detected by the formation of a blue indole dye after cleavage of 5-bromo-4-Chloro-3-indolyl-
13ß-galactopyranoside (X-gal). The cells were therefore mixed with 200 μl X-Gal (40 mg/ml 
dissolved in dimethylformamide) and 50 μl of 0.1 M isopropyl-ß-thiogalactosylpyranosid 
(IPTG). IPTG was added to induce the gene expression of the α-peptide. The insertion of a 
DNA fragment into the multiple cloning site of the pUC18 or pUC19 vector led to an 
interruption of the reading frame of the lacZ gene. Therefore, cells carrying recombinant 
plasmids appeared as white colonies whereas those that were blue had been transformed 
with non-recombinant plasmids (blue-white screen). 
4.1.3 Isolation and purification of nucleic acids 
4.1.3.1 Isolation of total RNA  
To inactivate RNases, amine-free solutions were treated for 12 h with 0.01 % (v/v) diethyl 
pyrocarbonate (DEPC) and autoclaved twice. Total RNA was extracted using peqGOLD 
RNAPure TM kit following the manufacturer’s protocol (Peqlab Bio technology, Erlangen). 
Briefly, 107 cells or 100 mg tissue were homogenized by pipetting in 1 ml peqGOLD 
RNAPure TM reagent. The sample was incubated at RT for 5 min followed by the addition of 
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0.2 ml chloroform and vigorous mixing for 15 sec and incubation for 5 min at RT. After 
centrifugation at 12000 g for 15 min at 4°C, the upper aqueous phase was removed carefully. 
An equal volume of isopropanol was added and the sample was incubated for 5 min at 4°C 
followed by centrifugation at 12000 g for 15 min. The supernatant was completely removed 
and the RNA pellet was washed four times with 80 % ethanol. The pellet was air dried and 
dissolved in 500 µl of RNase-free water. To obtain highly pure RNA, an additional ethanol 
precipitation step was performed using potassium acetate ( 4.1.3.4).  
4.1.3.2 Analytical quick preparation of plasmid DNA for sequencing 
For isolation of recombinant DNA from E.coli cells, a GeneEluteTM HP Plasmid Miniprep Kit 
(Sigma-Aldrich) was used. Cells were collected by centrifugation of 1.5 ml overnight culture 
for 5 min at 3000 rpm (Biofuge pico, Heraeus) and resuspended in 200 μl resuspension 
buffer containing 0.1 mg/ml RNaseA. 200 μl of alkaline lysis buffer was used to lyse the cells 
for 5 min before 350 μl neutralization buffer was added. Samples were centrifuged at 
13000 rpm for 10 min to sediment cell debris. A vacuum suction device was used for the 
subsequent steps of binding and washing of plasmid DNA to silica columns. The silica 
columns were attached to the device and equilibrated with 500 μl of preparation solution. The 
clear supernatant was applied to the column and fluid was sucked by vacuum whereas 
plasmid DNA was bound to the column. Then DNA was washed by the addition of 500 μl of 
wash solution 1 followed by 750 μl of wash solution 2. The column was transferred to a 2 ml 
micro-centrifugation tube and centrifuged for 1 min at 13000 rpm, before it was transferred 
into a fresh tube and plasmid DNA was eluted with 100 μl 10 mM Tris-HCl, pH 8.8 by 
centrifugation for 1 min at 13000 rpm. The yield and purity of the eluted DNA was analyzed 
spectrophotometrically ( 4.1.4.1) and by agarose gel electrophoresis ( 4.1.4.2).  
4.1.3.3 Electroelution of DNA fragments from agarose gels 
DNA fragments separated by gel electrophoresis ( 4.1.4.2) were cut from the gel and placed 
in sterile semipermeable dialysis tube (pore size 12 kDa; Sigma) and filled with 300 µl H2O. 
The tubes were tightly closed with clamps and transferred to a chamber filled with 1x TBE 
buffer. 135 mA current was applied for 45 min until the DNA was totally eluted into the buffer. 
DNA solution was then carefully collected and the tube was washed with 100 µl H2O to gain 
the remaining DNA solution. 
4.1.3.4 Ethanol precipitation of nucleic acids 
Ethanol precipitation [173] was used to concentrate and clean nucleic acid solutions. DNA 
was precipitated from the aqueous solution by addition of 250 mM NaCl and two volumes of 
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ethanol (-20°C) followed by centrifugation at 13000 rpm (Biofuge pico, Heraeus) for 20 min. 
The pellet was washed with 70 % ethanol (-20°C), dried in a vacuum evaporation centrifuge 
and finally dissolved in sterile water. To precipitate RNA, 0.3 M potassium acetate and 
2.5 volumes of ethanol was used and the RNA sediment was washed with 80 % ethanol 
diluted in RNase-free water. The isolated RNA was stored at -80°C and the DNA at -20°C. 
4.1.4 Analysis of nucleic acids 
4.1.4.1 Photometry 
A spectrogram of 1 µl nucleic acid solution was determined at a wave length of 200 to 
300 nm using Nanodrop1000 spectrophotometer (peqlab biotechnology, Germany). 
According to Lambert–Beer’s law, the concentration was calculated assuming that at an 
absorbance of 1, the concentration of RNA is 40 µg/ml and of DNA 50 µg/ml. The ratio of the 
absorbance of 260 nm and 280 nm was taken as a measure of the purity and should be 
between 1.7 and 2.0.  
4.1.4.2 Gel electrophoresis of DNA 
Negatively charged DNA molecules migrate in an electrical field towards the positive pole 
and can be separated in an agarose matrix according to their size. DNA molecules were 
visualized by Ethidium bromide (EtBr) which intercalates into the DNA double helix and 
fluoresces after excitation with UV light of 354 nm [174]. DNA samples and a DNA size 
standard, used to determine the molecular mass of the DNA samples, were both mixed with 
loading buffer.  Agarose gels were used in different concentration according to the size of the 
fragment. 0.8 % (w/v) gels were used to analyze DNA fragments ranging in size from 0.5 to 
8 kb, whereas 2 % (w/v) gels were used to analyze small fragments between 0.1 to 1 kb. 
Standard agarose (Roth) were used to prepare analytical gels whereas GTQ-agarose (Roth) 
was used for preparative gels. The gels were prepared by mixing the desired amount of 
agarose with 1x TBE buffer. The mixture was heated in a microwave oven to melt the 
agarose and then cooled down to 50°C by stirring. EtBr was added of a final concentration 
of 0.1 μg/ml before pouring the gel in a horizontal gel tray. The gel solidified at room 
temperature and was immersed in 1x TBE buffer in the electrophoresis chamber before use. 
10x TBE buffer (pH= 8.0)   
108 g/l  Tris-HCL 
55 g/l  Boric acid 
9.3 g/l  EDTA    
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6x loading buffer    
15 % (w/v) Glycerol or ficoll 
0.25 % (w/v) Bromophenol blue 
0.25 % (w/v) Xylene cyanol 
4.1.4.3 Gel electrophoretic analysis of RNA  
To assess the integrity and the quantity of RNA solutions, an Agilent 2100 bioanalyzer, the 
Agilent RNA 6000 Nano Kit® and a RNA 6000 Nanochip were used (Agilent technologies). 
The chip accommodates sample wells and a well for an external standard (ladder). On the 
chip, micro-channels are fabricated from glass that creates an interconnected network 
among the wells. When filled with a sieving polymer and fluorescence dye, the channels built 
an integrated electrical circuit that allows the separation of RNA as well as DNA and proteins. 
The RNA 6000 Nano gel matrix was centrifuged through a spin filter at 1500 g for 10 min at 
RT and could be stored at -80°C. Before starting a single assay, 1 µl of the RNA 6000 dye 
concentrate was added to 65 µl of the Nano gel matrix and the mixture was vortexed and 
centrifuged at 13000 g for 10 min at RT. The gel-dye mixture, the marker, the ladder and 
RNA samples (25-500 ng/µl) were loaded into the chip according to the manufacturer’s 
protocol. RNA samples were separated by their electrophoretic mobility and subsequently 
detected via laser induced fluorescence. From the electropherogram, the RNA integrity could 
be estimated and was indicated by the RNA integrity number (RIN, [175]). 
4.1.4.4  DNA sequencing 
Sequencing of plasmid DNA was performed by the StarSEQ® Sequencing Service (Mainz). 
400-700 ng of plasmid DNA was mixed with 1 µl sequence specific oligonucleotide primer 
(10 pmol/μl) in a total volume of 7 µl per sequencing reaction. Sequence informations were 
analyzed using the Accelrys Gene software. 
4.1.5 Amplification of nucleic acids using polymerase chain reaction (PCR) 
4.1.5.1 Reverse transcription of the total RNA 
Synthesis of cDNA was carried out using the SuperScript TM First-Strand Synthesis System 
(Invitrogen) following the manufacturer’s instructions. Briefly, in a total volume of 10 µl, 5 µg 
of total RNA, 1 µl oligo dT12-18 or 1 µl gene specific primer (10 µM each) and 1 mM dNTP mix 
were added, heated at 65°C for 5 min and then cooled on ice for 1 min. Thereafter, 2x 
reaction mix containing 2 µl of 10x reverse transcriptase buffer (200 mM Tris-HCl, 500 mM 
KCl, pH 8.4), 4 µl of 25 mM MgCl2, 1 µl of RNAse inhibitor (RNAse Out, 40 units / µl) and 2 μl 
0.1 M DTT was added to the mixture and incubated for 2 min at 42°C before 1 µl of 
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Superscript II reverse transcriptase (50 U/µl) was added and the reaction was incubated at 
42°C for 50 min. The reaction was stopped by incubation at 70°C for 15 min. In order to 
obtain RNA-free cDNA templates, the remaining RNA was digested by addition of 1 µl 
RNase H (2 U/µl) and incubated at 37°C for 20 min. cDNA samples were stored at -20°C. 
4.1.5.2 PCR for subcloning of DNA fragments 
DNA fragment were amplified in vitro by the activity of a thermostable DNA polymerase 
directed by a pair of sequence-specific oligonucleotide primers in the presence of dNTPs. 
The polymerase chain reaction (PCR) was initiated by a denaturation step in which the 
double-stranded DNA was denatured into two single DNA strands followed by annealing of 
the primers to their specific recognition sequence and their elongation by the polymerase 
corresponding to the template sequence. This cycle of denaturation, annealing and 
elongation was repeated up to 45 times leading to an exponential amplification of the 
template DNA. For amplification of fragments that were subcloned into plasmid DNA, 
Phusion polymerase (NEB) was used. Oligonucleotides primers used for PCR were designed 
to have an average melting temperature (Tm) of 64°C to 68°C.  
The following reaction was prepared: 
2 µl  Template cDNA 
10 µl  5x Phusion High Fidelity Buffer 
1 µl dNTPs (10 mM of dATP, dCTP, dGTP, dTTP) 
2.5 µl Oligonucleotide primer 1 (10 pmol/µl) 
2.5 µl Oligonucleotide primer 2 (10 pmol/µl)  
31.5 µl DEPC-treated H2O 
0.5 µl Phusion DNA Polymerase (2 U/µl) 
The following reaction cycle was performed: 
98°C 1min 
98°C 5 sec    
64°C 10 sec  45 cycles 
72°C 3min   
72°C 5 min 
4°C ∞ 
4.1.5.3 One-step RT-PCR 
The amplification of TRPM transcripts expressed in mouse intermediate and posterior 
pituitary cells was performed using the One-Step reverse transcription-PCR system 
(Invitrogen, Karlsruhe, Germany).  It allows the reverse transcription of RNA into cDNA and 
followed by its amplification in one single reaction tube (one-step). Therefore, RT/ Platinum® 
Taq Mix contains a mixture of two different enzymes: the SuperScript® II Reverse 
Methods  
 
 
 
40 
Transcriptase (RT) which exhibits reduced RNase H activity and increased thermal stability 
compared to Moloney Murine Leukemia Virus  reverse transcriptase RT (M-MLV RT) and 
Platinum® Taq DNA polymerase which is inhibited at ambient temperatures by the binding of 
a specific antibody. As soon as the denaturation step at 94°C begins, the polymerase activity 
is restored by the denaturation of the antibody.  
By adding the specific compounds (prepared as a supermix) directly to the tube containing 
the frozen sorted cells, the following reaction mixture was prepared: 
50  sorted pituitary cells ( 4.4) 
12.5 µl  2x reaction mix 
0.5 µl  RT/ Platinum® Taq Mix 
0.75 µl  Oligonucleotide primer 1 (10 pmol/µl) 
0.75 µl  Oligonucleotide primer 2 (10 pmol/µl)  
10 µl  autoclaved H2O 
The following reaction cycle was performed: 
Reverse transcription: 50°C  30 min 
PCR:    94°C 2 min  
    94°C 15 sec  
    62°C 40 sec  15 cycles 
    70°C 30 sec  
    94°C 15 sec    
    62°C 30 sec    30 cycles  
    70°C 40 sec + 2 sec/cycle   
    72°C 5 min 
    4°C ∞ 
Amplification products were analyzed by agarose gel electrophoresis ( 4.1.4.2)  
4.1.6 Enzymatic modification of nucleic acids 
4.1.6.1 Restriction mapping 
Restriction endonucleases and buffers from (NEB, Biolab) were used to cleave purified 
plasmid DNA. Plasmid DNA in a final concentration of 50-500 ng was digested using 1-10 U 
of restriction enzymes in the presence of the appropriate buffer provided by the manufacture 
(NEB) at recommended temperatures for 1-3 h followed by electrophoretic analysis of the 
digestion products ( 4.1.4.2). 
4.1.6.2 DNA phosphorylation  
PCR products that were amplified with oligonucleotide primers missing the 5'-phosphate-
residue were phosphorylated prior to ligation. For this purpose, the T4 polynucleotide kinase 
was used in the presence of ATP. 25 µl DNA solution was mixed with 3 µl 10x T4 DNA ligase 
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buffer containing 10 mM ATP (NEB) and 2 µl T4 polynucleotide kinase (10 U/µl, NEB). The 
reaction mixture was incubated at 37°C for 40 min and then the enzyme was inactivated at 
75°C for 10 min. 
4.1.6.3 Ligation of DNA fragments 
DNA fragments were inserted into linearized plasmid DNA by T4 DNA ligase. DNA fragments 
and plasmid vector were mixed in a molar ratio of 3:1 in a total volume of 15 µl containing 
1.5 µl 10x ligase buffer (NEB) and 1 µl T4 DNA ligase (NEB). The reaction was incubated 
overnight at 16°C or alternatively 3-4 h at room temperature. 
4.2 Protein biochemical technologies 
4.2.1 Protein extraction from mice organs 
Proteins from mouse tissues like pituitary gland and choroid plexus of the brain or cultured 
cells were extracted in RIPA buffer containing freshly added protease inhibitors. Tissues/cells 
were homogenized by pipetting under permanent cooling (4°C) and then sheared through 
0.9, 0.7 and 0.4 mm cannulas to solubilize the cellular proteins. Protein lysates were 
centrifuged at 12000 g at 4°C for 30 min and the supernatant was saved. Protein 
concentrations were estimated using the BCA protein assay kit (Pierce,  4.2.2). Afterwards, 
proteins lysates were mixed with the same volume of 2x Laemmli buffer and denatured for 
5 min at 95°C or 30 min at 37°C. 
RIPA-buffer (pH= 8.0) 
150 mM CaCl2 
50 mM Tris-HCl 
1 % (v/v) Nonidet P40 
0.5 %  Sodium deoxycholate 
0.1 % (w/v) SDS 
Protease inhibitors 
1 µg/ml   Leupeptin 
1 µg/ml   Antipain 
0.1 mM  PMSF  
1 µM   Benzamidin 
1 µM   Pepstatin A  
0.3 mM   Jodoacetamid  
0.3 µM  Aprotinin 
1 mM   Phenanthrolin C 
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2 x Laemmli buffer 
120 mM  Tris-HCl, pH 6.8 
8 % (w/v) SDS 
20 % (v/v) Glycerin 
0.01 % (w/v) Bromphenol blue 
10 % (v/v)  ß-mercaptoethanol (14.3 M freshly added before use) 
4.2.2 Determination of protein concentration 
Protein concentrations  were determined using the BCA method [176] and the BCA protein 
assay kit from Pierce® (Rockford, USA). The method is based on the fact that Cu2+ is 
reduced to Cu+ in an alkaline solution by the oxidation of peptide groups. The resulting Cu+ 
ions chelate with BCA forming purple-colored products which absorb light at 562 nm. The 
amount of this product is proportional to the amount of the proteins present in the solution. 
1:50, 1:100 and 1:250 dilutions of the protein lysate were prepared and three times 25 µl of 
each were pipetted into 3 wells of a 96-well plate. In parallel, 0.02, 0.04, 0.06, 0.08, 0.1, 0.15 
and 0.2 µg/µl BSA solutions were used to generate a calibration curve.  200 µl of a mixture of 
BCA reagent A and BCA reagent B (50:1) was added to each sample. The reaction was 
incubated at 37°C for 1 h and the absorbance was measured at a wave length of λ= 540 nm 
in a plate spectrophotometer (Tecan Sunrise, Switzerland).  The concentration of the tested 
protein was calculated using the standard calibration curve. 
4.2.3 Discontinuous sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
In an electric field, proteins were separated according to their molecular mass in the  
presence of sodium dodecyl sulfate (SDS) and polyacrylamide gel (PAGE, [177]). Proteins 
were denatured and molecules became negatively charged by their interactions with SDS. 
For the reduction of disulfide bonds, ß- mercaptoethanol was added to Laemmli buffer 
directly before use. Proteins samples, as well as a molecular mass standard (Precision Plus 
Protein™ Dual Color Standards, 10-250 kD; BioRad, München), were loaded into the 
pockets of the polyacrylamide gel.  Electrophoresis was carried out in 1x SDS buffer at 
75 volts until the migration front reached the resolving gel. Then 120 volts were applied. The 
content of polyacrylamide used to prepare the stacking and the resolving gels was adapted 
according to the size of proteins to be separated. To separate proteins with a molecular 
mass > 100 kD, 4 % and 6.5 % polyacrylamide were used in the stacking gel and the 
resolving gel, respectively. For the separation of proteins with a molecular mass of 20 – 
100 kD, 5 % and 10 % polyacrylamide were used. 
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Stacking gel 4 % or 5 % 
125   mM  Tris-HCl, pH 6.8 
0.1 %  (w/v)   SDS 
4 % or 5 % (v/v)   Acrylamid: Bisacrylamid (29:1) 
0.075 % (w/v)  APS 
0.15 %  (v/v)  TEMED 
Resolving gel 6.5 % or 10 % 
375  mM  Tris-HCl, pH 6.8 
0.1 %  (w/v)  SDS 
6.5 % or 10 % (v/v)  Acrylamid: Bisacrylamid (29:1) 
0.075 % (w/v)  APS 
0.15 %  (v/v)  TEMED 
10x SDS electrophoresis buffer 
250  mM  Tris-HCl, pH 8.3 
1.92  M  Glycin 
1 %  (w/v)  SDS 
4.2.4 Western blot analysis 
The aim of this technique is to transfer proteins separated by SDS-PAGE onto a membrane 
where they can be detected with antibodies. To assemble the so called blotting sandwich, a 
PAGE gel with separated proteins was covered with a nitrocellulose membrane (Hybond C 
extra; Amersham Biosciences; Piscataway/New Jersey). The gel and the membrane were 
placed between two pairs of Whatman 3 M filter paper and a pair of pads which were rinsed 
with blotting buffer. The blotting sandwich was then placed in a blotting chamber (Peqlab 
Biotechnologie, Erlangen) filled with blotting buffer. A current of 350 mA was applied for 
90 min at 4°C to transfer the negatively charged proteins from the gel to the positively 
charged membrane where the proteins became tightly attached by the hydrophobic 
interaction with the membrane. 
 Blotting buffer (pH= 8.3) 
20 %  Methanol 
10 %  10x SDS electrophoresis buffer 
To check the transfer efficiency, the membrane was transiently submersed in a solution of 
2 % of the dye Ponceau-S in 3 % trichloroacetic acid. The membrane used for blotting had 
high affinity for proteins and therefore, the unoccupied areas were blocked by shaking the 
blot in 5 % non-fat dry milk dissolved in TBST for at least 1 h at RT. The membrane was 
submersed overnight at 4°C with gentle shaking in a solution containing primary antibodies 
dissolved in 1 % BSA / TBS / 0.05 % NaN3 (Table  3-5). 
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10x TBS 
500 mM Tris-HCl pH 7.5 
1.5 M  NaCl 
TBST 
1x  TBS 
1 %  Tween 20 
4.2.5 Enhanced chemiluminescence development (ECL-Reaction) 
The primary antibody ( 4.2.4) was discarded and the nitrocellulose membrane was washed 
three times for 10 min at RT with TBST and then incubated with secondary antibodies 
coupled to horseradish peroxidase in 5 % solution of non-fat dry milk for 1 h at RT. Next, the 
membrane was washed two times 10 min with TBST and finally for 10 min with TBS. The 
ECL reagents A and B containing the substrate of horseradish peroxidase (Perkin Elmer, 
Waltham/Massachusetts) were mixed in 1:1 ratio and added to the blot. The 
chemiluminescent reaction product was visualized and subsequently quantified for 15 sec, 
1 min, 5 min and 60 min using a charge-coupled device (CCD) camera (LAS-3000; Fujifilm, 
Düsseldorf) 
To remove antibodies bound to the blot (stripping), the membrane was washed four times for 
5 min with TBST, incubated with 20 ml of stripping buffer at 55°C with shaking, washed six 
times for 5 min with 20-30 ml TBST and finally blocked in 20 ml 5 % non-fat dry milk in TBST 
before it was incubated with the another antibody. 
Stripping buffer 
62.5 mM Tris-HCl pH 6.8 
2%  SDS 
100 mM ß-mercaptoethanol 
4.3 Immunostaining 
4.3.1 Fixation of proteins by whole body perfusion of mice 
The goal of the perfusion fixation of the whole body with a fixative is to preserve the tissue 
morphology and retain the antigenicity of the target molecules for following immunostaining 
experiments. The vascular system of an anesthetized mouse was used to deliver the fixative 
in vivo to the organs to fix proteins before autolysis of cells begins. The method described 
below is used to fix the organs which are supplied by the left ventricle. The perfusion was 
performed inside a fume hood. Before starting the procedure, the whole tubing of the 
perfusion system were filled with PBS (37°C) and all air bubbles were removed. Mice were 
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anesthetized with a mixture of ketamine (Serumwerk, Bernburg) and xylazine (Rompun, 
Bayer, Leverkusen) in concentration of 140 µg/g body weight and 10 µg/g body weight, 
respectively. As a measure of persisting nociception and the deepness of anesthesia, the 
withdrawal reflex upon strong pinching of the hind paw was tested repetitively. Thereafter, 
the mouse was taped on a tray with the chest upward and the abdominal site was cleaned 
with 70 % ethanol. A midline skin incision from the thoracic inlet to the pelvis was made with 
a scissor and then the abdomen was opened carefully to expose the liver and intestines. To 
expose the heart, the thoracic cavity was opened by an incision down the midline of the 
sternum, removing the diaphragm and by cutting the ribs along the lateral surface on the 
right and left side. Then the pulsative heart was gently grasped using a forceps and a blunt 
butterfly injection needle connected to a tube filled with PBS was inserted directly into the 
apex of the left ventricle. The right atrium was incised to allow the perfused solutions to exit 
the circulation. 20-40 ml PBS was perfused slowly and constantly into the heart to flush the 
blood from the circulatory system. Blanching of the liver and the mesenteric arteries from 
blood were good indicators to start the perfusion with the fixative. 60-80 ml of 4 % 
paraformaldehyde (PFA)/PBS was perfused for a mouse with body weight of 20-30 g. 
Skeletal muscle contractions indicated successful and complete perfusion of the body. 
Finally, the pituitary gland was dissected and post-fixed for additional 15-30 min in ice cold 
4 % PFA/PBS.  
Phosphate buffered saline (PBS) (pH= 7.4)  
137 mM NaCl  
2.7 mM KCl  
10 mM Na2HPO4  
1.47 mM KH2PO4 
4.3.2 Preparation of pituitary microsections for immunostaining  
Following the fixation process, the fixed pituitaries were washed with PBS three times for 
2 min and transferred into 30 % sucrose overnight to remove PFA and to cryo-protect the 
tissues. Pituitaries were placed in disposable plastic molds (Peel-A-Way ®, Thermo Fisher) 
filled with Jung tissue freezing medium (Leica Microsystems GmbH). A snap freezing 
chamber was made of a coplin jar filled with isopentane up to a height of 1 cm which was 
placed in an ice box filled with dry ice and 100 % ethanol up to a height of 3-4 cm. The molds 
were placed in the isopentane until the tissue freezing medium was totally frozen. Frozen 
organs were wrapped with parafilm and stored at -80°C at least overnight before they were 
cut into micro-sections. Using a CM3050 S microtome (Leica), 14 µm-slices were placed 
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onto SuperFrost® plus glass slides (R. Langenbrinck) and stored in slide saver boxes at -
80°C. 
4.3.3 Immunohistochemistry 
The immunostaining procedure was started by washing the slices ( 4.3.2) with PBS three 
times for 10 min at RT to remove Jung tissue freezing medium. Next, the slices were next 
permeabilized and blocked by incubation of the slides in coplin jars containing 20-50 ml of 
blocking solution. Depending on the amount of antibodies available, the staining procedure 
was performed either by incubation of the slides in coplin jars containing 20-50 ml of primary 
antibody solution (Table  3-4) dissolved in PBS or alternatively by the application of at least 
50 µl of antibody solution on the top of each slice followed by incubation of the slides in a 
humidified chamber overnight at 4°C. Control slices excluding the primary antibodies were 
always included (only shown in Figure  5-18) and never showed signals different from the 
background. Excess antibody was washed three times for 20 min with PBST in a coplin jar. 
The secondary antibody (Table  3-4) was diluted in PBS and applied for 2 h at RT in the dark. 
Excess secondary antibody was washed three times for 10 min with PBST. For staining of 
the cell nucleus, Hoechst 33258 (Sigma) was prepared in a concentration of 5 µg/µl in PBS, 
applied for 10 min at RT and then washed two times for 2 min with PBST. To reduce the 
decrease of fluorescence, stained slices were covered with a drop of anti-fading agent Roti®-
Mount FluorCare (Roth) and then with glass coverslips. Glass slides were sealed with nail 
polish to avoid desiccation. 
Blocking solutions 
5 % normal goat serum in 0.2 % Triton-X 100/ 0.02 % NaN3/ PBS 
5 % normal donkey serum in 0.2 % Triton-X 100/ 0.02 % NaN3/ PBS 
PBST 
1x PBS 
1% Tween 20 
Stained slices were analyzed using an Observer. Z1 fluorescence microscope (Carl Zeiss 
AG, Göttingen) coupled to a CCD camera and photos were acquired and archived by 
Axiovision Rel.4.6 image processing software (Carl Zeiss AG, Göttingen). To compare 
fluorescence emission intensities observed in different samples, slices were illuminated with 
identical light intensities and for identical time intervals. 
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4.4 Fluorescence-activated cell sorting (FACS)  
For fluorescence-activated cell sorting (FACS), pituitary cells were prepared as described 
under ( 4.1.1.2). Following centrifugation, the cells were kept on ice until being sorted. In 
some cases the cells were stained with anti-GLAST antibodies (1:11) in 0.5 % BSA/PBS for 
10 min at 4°C and the excess antibody was washed with 0.5 % BSA/PBS. Cell sorting was 
performed by Dr. Stephan Philipp on a MoFlo-XDP cell sorter (Beckman Coulter, Germany) 
using a 488 nm laser excitation. 
4.5 Fluorescence-based Ca2+ imaging 
For Ca2+ imaging experiments, pituitary cells were prepared as described under ( 4.1.1.2). For 
functional analysis of TRPM3 channel, changes of the intracellular Ca2+ concentration [Ca2+]i 
were recorded using Fura-2. Fura-2 is a ratiometric fluorescent dye excited by light of 340 
nm and 380 nm wavelengths [178]. Upon binding of Ca2+, Fura-2 changes its excitation 
maximum which shifts from 380 nm towards 340 nm whereas the emission maximum at 510 
nm is an affected. As a consequence, the ratio of the fluorescence intensities successively 
measured after excitation with 340 nm and 380 nm (F340/F380) is a good measure of [Ca2+]i. 
This ratio is independent of dye concentration, cell thickness, excitation intensity, dye 
leakage, photo-bleaching as well as the camera sensitivity because these factors all affect 
the measurements at both excitation wavelengths to the same extent. Fura-2 is used as an 
acetoxymethyl ester (Fura-2 AM), a nonpolar substance which can pass the plasma 
membrane of the cell. Fura-2 AM is cleaved in the cytoplasm of the cell by endogenous 
esterases to the polar molecule Fura-2 which is no longer able to pass the cell membrane 
again.  
Measurements were performed on an inverted microscope (Carl Zeiss AG; Göttingen) 
equipped with a 20x Flour objective and a polychrom II illumination system that can switch its 
output wavelength within 3 ms (TILLVision-Systems, TILL Photonics; Gräfelfing). 1 mM Fura-
2 AM stock solution were prepared in dimethyl sulfoxide (DMSO).  Primary pituitary cells 
plated onto poly-L-lysine covered coverslips were loaded at 37°C for 30 min in the dark with 
5 µM Fura-2 AM (Biotium, Austria) in the medium. Cells were washed twice with Ringer’s 
solution before the coverslip was inserted into a perfusion chamber. The cells were perfused 
with a perfusion rate of 1 ml/min. 100 µM pregnenolone sulfate (PregS) dissolved in Ringer’s 
solution was used to activate TRPM3, whereas 10 µM Hesperetin was used to block the 
channel activity. Both PregS and Hesperetin were prepared as a stock solution of 100 mM in 
DMSO. F340/F380 ratios were obtained every 3 sec and the fluorescence emissions at λ > 440 
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nm were captured, digitized, and analyzed for individual cells after background subtraction 
using TILLVision software. Results were given as mean ± S.E.M. 
Ringer’s solution 
135 mM NaCl 
5.4 mM KCl 
2 mM MgCl2 
1 mM CaCl2 
20 mM glucose 
10 mM HEPES 
pH = 7.25 adjusted with NaOH, 315 mosmol/kg 
4.6 Electrophysiological recordings (Dr. Andreas Beck) 
For patch-clamp experiments, cells from the posterior and intermediate lobe were prepared 
as described under ( 4.1.1.2). High resolution current recordings were performed at room 
temperature in the tight-seal whole-cell configuration using an EPC-9 patch-clamp amplifier 
(HEKA Electronics, Lambrecht, Germany). Patch pipettes were pulled from glass capillaries 
GB150T-8P (Science Products, Hofheim, Germany) at a vertical Puller (PC-10; Narishige, 
Tokyo, Japan) and had resistances between 2 and 4 MΩ. All bath and pipette solutions had 
an osmolarity of 285 to 305 mosM. For the recording of voltage-activated sodium current 
(NaV) and TRPM3 currents, voltage ramps spanning from -100 mV to +100 mV within 50 ms 
from a holding potential (Vh) of -80 mV (NaV) or within 400 ms from a Vh of 0 mV (TRPM3) 
were applied every 2 s using the patchMaster software (HEKA).  All voltages were corrected 
for a 10 mV liquid junction potential. Currents were filtered at 2.9 kHz and digitized at 100 µs 
intervals. Capacitive currents and series resistances were determined and corrected before 
each voltage ramp using the automatic capacitance compensation of the EPC-9. Inward and 
outward currents were extracted from each individual ramp current recording by measuring 
the current amplitudes at -80 and +80 mV, respectively, and plotted versus time. 
Representative current-voltage relationships (IVs) were extracted at the indicated time 
points. To display the IVs of the net PregS-induced current, basic currents before application 
of PregS were subtracted. All currents were normalized to the cell size 
(picoamperes/picofarads). 
Bath solution 
140 mM  NaCl 
2.8 mM  KCl 
2 mM  MgCl2 
1 mM  CaCl2 
10 mM  HEPES 
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10 mM  glucose 
Pipette solution 1 
140 mM  Cs- Glutamate 
8 mM  NaCl 
1 mM  MgCl2 
10 mM  HEPES 
10 mM  Cs-BAPTA + 3.1 mM CaCl2 => 100 nM free Ca2+ (calculated with webMaxC, 
http://web.stanford.edu/~cpatton/webmaxcS.htm) 
This solution was used for (Figure  5-40, Figure  5-42). 
Pipette solution 2 
140 mM  Cs- Methanosulfonate 
8 mM  NaCl 
1 mM  MgCl2 
10 mM  HEPES 
10 mM  Cs-BAPTA + 3.1 mM CaCl2 => 100 nM free Ca2+ (calculated with webMaxC, 
see above) 
This solution was used for all other electrophysiological experiments. 
Application solution 
100 µM PregS in bath solution 
10 µM Hesperetin in bath solution 
Monovalent-free (MVF) solution  
140 mM NMDG-Cl 
2 mM  MgCl2 
1 mM  CaCl2 
10 mM  HEPES 
10 mM  glucose  
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5 Results 
5.1 Identification of TRPM3 transcripts in mouse pituitary gland 
5.1.1 Detection of TRPM3 transcripts in whole pituitary  
Northern blot analysis revealed TRPM3 expression in the pituitary gland and other tissues of 
the mouse with transcripts of different sizes [108]. The Trpm3 gene encodes a large number 
of variants due to alternative splicing of their primary transcript (Figure  2-7). Furthermore, the 
variability of TRPM3 transcripts is increased by the presence of at least three promoters that 
give rise to three alternative transcription start sites and lead to alternative amino-termini of 
the encoded proteins.TRPM3α variants start with exon 1 and lack exon 2 but TRPM3β 
variants start with exon 2. Thus, the presence of exon1 and exon2 in the transcripts is 
mutually exclusive. Furthermore, isoforms have been described starting with an ATG-codon 
located at the very end of exon 4, which is the start codon for transcripts lacking both exon 1 
and 2 ([106], Figure  2-7).  
To analyze the identity of TRPM3 transcripts present in the mouse pituitary, I isolated total 
RNA which was reversed transcribed using oligo (dT) primers and amplified by PCR. Using 
forward primers PH383 located in exon1 in combination with different reverse primers 
PH385, PH386, PH561 and PH562 located in exon 28 (Figure  5-1), I found PCR products 
matching in size to a complete reading frame of TRPM3 α-variants. No amplification products 
of corresponding size were obtained using forward primer PH429 in combination with the 
same set of reverse primers indicating no or low expression of TRPM3 β-variants. Strong 
bands were obtained using primer PH384 which hybridize to the common exon 3 indicating 
prominent expression of TRPM3 proteins whose translation start codon is located at the very 
end of exon 4. Such TRPM3 proteins have already been described in human [102] and the 
result is in good agreement with recent findings of Alexander Becker who demonstrated that 
nearly 70 % of the TRPM3 transcripts present in the pituitary encode proteins with truncated 
amino termini [179]. 
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Figure  5-1: Amplification of TRPM3 cDNA from mouse pituitary gland.  
(A) Schematic representation of the coding exons of TRPM3. Start codons (ATG) present in exon 1, 2 
and 4 and a stop codon (stop) in exon 28 are indicated in green and red, respectively. Forward and 
reverse primers used to amplify TRPM3 cDNA are presented by arrows. (B) Gel electrophoretic 
separation of RT-PCR products obtained from mouse pituitary gland or a no template control using 
different primer combinations as indicated. Products matching to the appropriate size of the expected 
products are labeled with arrows. Additional bands of low size might be related to mispriming during 
PCR.   
5.1.2 Analysis of splice events in TRPM3 transcripts of the pituitary  
RT-PCR experiments using primers located upstream of the translations start codons in exon 
1, 2 or 3 combined with a downstream primer PH385 located downstream of the stop codon 
confirmed my previous findings (Figure  5-1): primers PH429 and PH385 again failed to 
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amplify TRPM3 transcripts, indicating the absence of ß-variants in the mouse pituitary which 
is in contrast to what has been described for the mouse choroid plexus [111]. However, when 
I combined the downstream primers PH385 with primers PH383 located upstream of a start 
codon in the predicted exon 1, I obtained amplification products of ~ 5.2 kb similar to what I 
found before (compare to Figure  5-1).  
 
Figure  5-2: Amplification of TRPM3 cDNA from mouse pituitary gland.  
(A) Strategy for the amplification of TRPM3 cDNA from mouse pituitary gland. Arrows indicate the 
position of the primers. (B) PCR products obtained after separation by gel electrophoresis. Fragments 
used to analyze the TRPM3 transcriptome of the pituitary are highlighted which were common to all 
TRPM3 isoforms. 
I analyzed the splicing frequency between exon 3 and exon 28. For that purpose, I subcloned 
the amplification products obtained with primers PH384 and PH385. Sequencing of 98 
independent clones identified 12 different combinations of alternative splice events that 
happened in five different exons 8, 13, 15, 17 and 20 (Figure  5-3). Four of them displayed 
splicing within the reading frame, whereas splicing in exon 20 led to a truncation of the 
protein upstream of the transmembrane region due to splicing outside of the reading frame. 
Exons 8, 15 and 17 were removed by exon skipping whereas in exons 13 and 20, a part of 
the exons were removed using an alternative 5´splice site.  
Confirming the results obtained by one-step RT-PCR (Figure  5-4), I did not find any clone 
containing the long pore encoding sequence of exon 24 (Table  5-1). Thus, all TRPM3 
channels expressed in the pituitary are expected to be permeable for Ca2+. The second most 
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frequent splice event happened in exon 8 (76.5 %, Table  5-1) and correspondingly, variant 1 
was most abundant with a rate of close to 40 % of all variants found. Splicing within exon 13 
was rare. Only ~ 3 % of the clones lacked the ICF-encoding region. Thus, most of the 
TRPM3 proteins may encode functionally active subunits of TRPM3 cation channels.  
Table  5-1: Frequency of splice events in TRPM3 mRNA of the pituitary gland. 
Spliced exon No. 8 13 15 17 20 24 
[%] 76.5 3.06 42.8 8.16 3.06 100 
  
 
Figure  5-3: Cloning of TRPM3 splice variants in mouse pituitary gland. 
The organization of TRPM3 cDNA is shown in yellow with each box representing an individual exon. 
Exons which are alternatively spliced are highlighted in orange and defined by their numbers. 
Sequences encoding transmembrane regions are highlighted in gray and the alternative aminotermini 
are shown in green. The locations of primers used to amplify the cDNA are indicated. Identified 
TRPM3 variants are shown as black boxes and their frequency is indicated. Areas missing by 
alternative splicing are presented as dotted line. 
5.1.3 Identification of TRPM3 transcripts in different regions of the pituitary 
I analyzed the presence of TRPM3 transcripts in different pituitary lobes by RT-PCR. The 
anterior lobe was dissected from the intermediate/posterior lobe from three different mice 
and total mRNA was prepared. One-step PCR ( 4.1.5.3) was performed using two primer 
combinations PH928/PH930 and PH777/PH778 which hybridize to exons 12/13 and to exons 
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24/25, respectively. The latter primer combination allowed the identification of alternative 
splicing within the pore coding exon 24, which was indicated by a shortened amplification 
product of 187 bp. As shown in Figure  5-4, amplification products of the expected size (109, 
187 bp) indicated expression of TRPM3 transcripts in both pituitary regions of all three 
samples. Interestingly, only products of 187 bp were obtained using primers PH777/PH778 
indicating the absence of transcripts encoding Ca2+-impermeable long pore variants. 
 
Figure  5-4: Expression of TRPM3 transcripts in the anterior and in the intermediate/posterior 
lobe of the pituitary gland.  
(A) Schematic representation of the coding exons of TRPM3. Oligonucleotide primers (arrows) 
flanking the region between exon 12 and exon 13 and the pore coding exon 24 and 25 were used to 
amplify TRPM3 cDNA. (B) Gel electrophoretic separation of PCR products obtained from anterior lobe 
(AL) and intermediate/posterior lobe (IL/PL) of the pituitary using primers shown in (A) in three 
individual RNA preparations. NTC = no template control. 
5.1.4 Distribution of TRPM transcripts in FACS-sorted cells of the posterior 
lobe/intermediate lobe 
In contrast to the adenohypophysis which contains at least five types of neuroendocrine cells 
and in addition folliculostellate cells, the posterior lobe (PL) mainly consist of axon terminals 
of hypothalamic neurons and one single glial cell type called pituicytes. These cells are 
reported to express glutamate aspartate transporter proteins (GLAST) which can be taken as 
a cellular marker of these cells. Similarly, the intermediate lobe (IL) also contains mainly one 
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single cell type: α-MSH releasing melanotrophs which may not express the glial cell surface 
marker GLAST. To dissect the origin of TRPM3 transcripts obtained from RNA of the 
intermediate lobe/posterior lobe ( 5.1.3), cells from PL/IL of wild type pituitaries were prepared 
and the living cells were stained with anti-GLAST antibodies in a dilution of 1:11 in 0.5 % 
BSA/PBS for 10 min on ice. After sorting of 50 GLAST-positive and GLAST-negative cells 
each in single tubes by fluorescence-activated cell sorting (FACS, see also  5.4.2.4), one-step 
RT-PCR was performed to analyze the expression of TRPM3 transcripts (Figure  5-5). 
Again different primer combinations to identify splice events within exon 13 (PH885/ PH907) 
and exon 24 (PH521/PH522) were included, as well as primer pairs (PH400/PH395, 
PH374/PH405) common to all splice variants.  Using primers PH521/PH522 specific to exon 
24 and exon 25 in both GLAST-positive and GLAST-negative cells, 119 bp fragments were 
amplified. These fragments derived from transcripts which were spliced within exon 24 and 
suggested the presence of Ca2+-permeable channel in these cells.  
 
Figure  5-5: Analysis of TRPM3 transcripts expressed in GLAST-positive and GLAST-negative 
cells from intermediate/posterior lobe of the pituitary gland. 
(A) Schematic representation of the coding exons of TRPM3. Oligonucleotide primers (arrows) 
flanking the region between exons 4 and 5, exon 12 and 13, the pore coding exon 24 and 25 and 
exon 27 and 28 were used to amplify TRPM3 cDNA. (B) Gel electrophoretic separation of PCR 
products obtained from brain RNA (as positive control) and from cells that were stained with anti-
GLAST antibodies (GLAST pos.) or not (GLAST neg.) using primers shown in (A). NTC = no template 
control. The expected sizes of the amplification products are indicated. 
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The aim of using primers PH885 and PH907 was to explore the splice events within exon 13, 
which may lead to the removal of a protein domain indispensable for channel function (ICF, 
[111]). The expected lengths of the amplified fragments were 204 or 150 bp, respectively. 
Only fragments originating from an unspliced exon 13 were amplified from both cell 
populations (Figure  5-5) indicating the absence of the non-functional variants in pituicytes as 
well as in melanotrophs.  
In addition to TRPM3 isoforms, I also analyzed the expression of other members of TRPM 
subfamily (Figure  5-6) using gene-specific primer pairs. TRPM3, TRPM4 and TRPM7 
transcripts were amplified in GLAST-positive cells (pituicytes) whereas in GLAST-negative 
cells (melanotrophs), TRPM2, TRPM3, TRPM4, TRPM6 and TRPM7 transcripts were 
amplified.  
 
Figure  5-6: Expression of TRPM transcripts in GLAST-positive and GLAST-negative cells from 
the intermediate/posterior lobe of the pituitary gland. 
Gel electrophoretic separation of PCR products obtained from brain RNA (as positive control) and 
from cells that were stained with anti-GLAST antibodies (GLAST pos.) or not (GLAST neg.) using 
primers specific for TRPM1-TRPM8 transcripts. NTC = no template control. The expected sizes of the 
amplification products are indicated. Yellow arrows label unspecific PCR products (primer dimers).  
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5.2 Identification of TRPM3 proteins in mouse pituitary gland using anti-
TRPM3 antibodies 
5.2.1 Detection of TRPM3 proteins by western blot 
I analyzed the expression of TRPM3 proteins in the pituitary gland by western blot using 
affinity purified monoclonal anti-TRPM3 antibodies (9F6) which recognize an epitope within 
the C-terminus of the protein (Figure  5-7, A). In pituitary glands and choroid plexus of the 
brain from wild type (WT) mice, I found proteins that matched to recombinant TRPM3α2 
proteins expressed in HEK293 cells (HEK-TRPM3α2, Figure  5-7 B) and to the expected 
molecular mass of 194.794 kDa calculated from the primary TRPM3α2 sequence. Similar 
bands were missing in protein extracts from the pituitary gland and choroid plexus obtained 
from TRPM3-deficient mice (KO, Figure  5-7 B), demonstrating that the antibody detected the 
right protein. However, other proteins of lower mass that might be unrelated to TRPM3 were 
also detected by the antibody. The data provides strong evidence that TRPM3 proteins are 
expressed in the pituitary. Interestingly, TRPM3 proteins found in the choroid plexus were 
slightly smaller and may represent different TRPM3 isoforms.  
A polyclonal anti-TRPM3 antibody AK695 raised against the sequence 
QEKEPEEPEKPTKEK within the N-terminus of mouse and rat TRPM3 proteins (Figure  5-7, 
A), also detected protein of similar molecular mass as the recombinant protein in protein 
extract from WT pituitaries that were not detected in TRPM3-deficient mice (KO, arrow in 
Figure  5-7 C). Again TRPM3 proteins of lower molecular mass were identified in the choroid 
plexus of the brain. However, these antibodies also detected unrelated proteins of similar 
size that were still present in tissues from the KO. Taken together, the data confirmed my 
finding obtained with RT-PCR and demonstrate TRPM3 expression in the pituitary and the 
choroid plexus. 
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Figure  5-7: Expression of TRPM3 proteins in mouse tissues.  
(A) Schematic presentation of the TRPM3 protein with six transmembrane domains. The epitopes of 
anti-TRPM3 antibody 9F6 at the C-terminus and AK695 at the N-terminus are indicated. (B) Western 
blot using 9F6 antibodies to detect TRPM3 proteins in pituitary gland and choroid plexus from WT and 
KO mice. HEK293 cells stably expressing TRPM3α2 (HEK-TRPM3α2) served as positive control. Anti-
Na+/K+ ATPase antibodies were used as loading controls. (C) Western blot using antibody AK695 to 
detect TRPM3 proteins in pituitary gland and choroid plexus from WT and KO mice. 
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5.2.2 Immunohistochemical detection of TRPM3 proteins 
I used the antibodies tested in western blot ( 5.2.1) to analyze TRPM3 expression in the 
pituitary by immunohistochemical staining. For this purpose, age and sex-matched WT and 
KO mice were perfused transcardially with 4 % PFA ( 4.3.1) and 14 µm pituitary slices were 
prepared from both genotypes ( 4.3.2). Using monoclonal 9F6 antibodies in different dilutions, 
TRPM3 proteins were not detectable probably due to low affinity of the antibodies or masking 
of the epitope in fixed tissues (not shown). Using polyclonal AK 695 antibodies in a 1:1000 
dilution, I found strong signals in the intermediate lobe of the pituitary (Figure  5-8). These 
signals were largely reduced in the anterior lobe which was co-stained with anti-LH 
antibodies as a marker of gonadotropic cells. However, these signals were also present in 
the pituitary from TRPM3-deficient animals (Figure  5-8) even with increased intensity, 
indicating false positive signals of the antibodies as it was the case in western blot ( 5.2.1). 
On the other hand, AK695 antibodies may recognize truncated TRPM3-proteins present in 
KO-animals, since the recognized epitope is located N-terminally of the targeted pore region. 
 
Figure  5-8: Distribution of immunoreactivity to anti-TRPM3 antibodies (AK695) in the anterior 
(AL), intermediate (IL) and posterior lobe (PL) of the pituitary gland.  
Fluorescence images of 14 µm pituitary sections prepared from WT and KO mice and stained with AK 
695 (green), anti-LH (red) and Hoechst 33258 for nucleus staining (blue). Overlays of AK695 and LH 
staining are shown on the right. Scale bar = 50 µm. 
Therefore, tissues from TRPM3-KO mice might be an inappropriate control for 
immunohistochemical experiments using these antibodies and, the experiment was repeated 
with pituitary sections from WT animals (Figure  5-9). As controls, the antibodies were 
incubated with a 10000-fold molar excess of peptide P873. This peptide has the amino-acid 
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sequence of QEKEPEEPEKPTKEK and was used for immunization to obtain the antibody. 
As a negative control, I used an unrelated control peptide P281. Similar to the last 
experiment, I found strong signals in the intermediate lobe which was largely reduced in the 
neighboring areas. In the presence of P873 but not P281, the signals disappeared indicating 
that at least the antibodies recognized (a) protein(s) containing an epitope similar to the 
sequence of P873. Taken together these data provide first and preliminary evidence that 
TRPM3 channels are expressed in the intermediate lobe of the pituitary. On the other hand, it 
is pretty clear from these data that neither 9F6 nor AK695 antibodies are reliable and specific 
tools to identify TRPM3 expressing cells in the pituitary. 
 
Figure  5-9: Distribution of immunoreactivity to anti-TRPM3 antibody (AK 695) in the pituitary 
gland.  
Fluorescence images of 14 µm pituitary sections prepared from WT mice and stained with AK695 
(green) alone or after preincubation with a 10000-fold molar excess of peptide P873 or P281, anti-LH 
(red) or Hoechst 33258 for nucleus staining (blue). Overlays of AK 695 and LH staining are shown on 
the right.  Scale bar = 50 µm. 
5.3 Analysis of TRPM3 expression using GFP-Ki mice  
As shown in the previous chapter ( 5.2), anti-TRPM3 antibodies provided strong evidence that 
TRPM3 is expressed in the pituitary. However, my data also demonstrated that these 
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antibodies were rather unsuitable to identify TRPM3 expressing cells within this tissue. 
Therefore, I chose an alternative approach and made use of TRPM3-GFP-Knock in (GFP-Ki) 
mice which carry an IRES-GFP-cassette within the TRPM3 gene locus (Figure  3-2). These 
mice should express the enhanced green fluorescent protein (EGFP) under the control of the 
TRPM3 promoter(s). 
5.3.1 GFP-Ki mice as a model to analyze TRPM3 expression 
Since this mouse line has not been characterized before, I checked whether it is an 
appropriate model to analyze TRPM3 expression in the pituitary gland.   
5.3.1.1 Detection of the green fluorescence of GFP in GFP-Ki mice by FACS 
First, I analyzed the green fluorescence of GFP in vital cells from tissues, where TRPM3 
expression has already been described, and compared it to pituitary cells. For that purpose, 
single cells were prepared from both pituitary gland and choroid plexus of the brain and were 
tested by FACS (Figure  5-10). Cells isolated from WT mice served as negative controls. 
 
Figure  5-10: FACS analysis of tissues from GFP-Ki mice.  
GFP-fluorescence histograms (log scale) comparing cells from choroid plexus and pituitary gland of 
wild type (WT) and TRPM3-GFP-Ki (GFP-Ki) mice. 
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As shown in Figure  5-10, FACS analysis of choroid plexus cells from GFP-Ki mice showed a 
strong rightward shift of the fluorescence peak compared to control cells indicating that more 
than 70 % of the cells were green fluorescent. This is in good agreement with the finding that 
TRPM3 is expressed in the epithelial cells of the choroid plexus [103] which provide the main 
fraction of cells within this tissue. It demonstrates that green fluorescent proteins are 
expressed in TRPM3 expressing tissues of GFP-Ki mice. In cell preparations of the pituitary 
gland, I also noticed green fluorescent cells. However, their proportion was only 3 % 
indicating that only few cells express TRPM3 within this multifunctional tissue.  
5.3.1.2 Detection of TRPM3 proteins in tissues of GFP-Ki mice 
The targeting strategy of the TRPM3 gene locus included the insertion of a splice acceptor 
site (SA) into the L3F1 allele (GFP-Ki), with the intention that the IRES-GFP sequence 
should be fused to exon 24 and the TRPM3 reading frame should be interrupted by stop 
codons present in the sequence of the IRES-GFP cassette (Figure  3-2). Therefore, only 
truncated non-functional TRPM3 proteins should be formed in TRPM3 GFP-Ki/GFP-Ki mice which 
are homozygous for the GFP-Ki allele. 
In western blots, I tested, whether full length TRPM3 proteins are generated in the pituitary 
gland and choroid plexus in different mouse lines containing targeted TRPM3-alleles. For 
that purpose, I used monoclonal 9F6 antibodies which recognize an epitope C-terminally 
located from the targeted pore region (Figure  5-7, A). To my surprise, I found that entire 
TRPM3 proteins were present each in the pituitary glands pooled from five mice that were 
homo- or heterozygous for the GFP-Ki (L3F1) allele (Figure  5-11). In contrast, I found a 
gene-dose-dependent reduction of TRPM3 proteins in the choroid plexus from the very same 
mice leading to complete absence of TRPM3 in homozygous GFP-Ki mice.  The data 
suggest that TRPM3 channels are unaffected in the pituitary gland but functionally inactive in 
the choroid plexus of TRPM3 GFP-Ki/GFP-Ki. 
Using anti-GFP antibodies I also tested the presence of GFP proteins in GFP-Ki mice. In the 
choroid plexus I found a gene-dose-dependent presence of GFP proteins. However, in the 
pituitary gland no GFP proteins were detectable probably due to the lower number of cells 
expressing TRPM3 in this tissue (compare Figure  5-10) 
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Figure  5-11: Expression of TRPM3 proteins in different mouse lines.  
Western blot using 9F6 antibodies to analyze TRPM3 proteins in pituitary gland and choroid plexus of 
mice heterozygous (M3WT/GFP-Ki) or homozygous (M3GFP-Ki/GFP-Ki) for the L3F1 allele shown in 
comparison to tissues from wild type (WT) and TRPM3-deficient mice (KO, L1 allele). The blot was cut 
into three pieces, which were tested with anti-TRPM3 antibodies (9F6), anti-GFP antibodies and anti-
Na+/K+-ATPase antibodies as a control of comparable amounts of proteins loaded to each lane.  
5.3.1.3 Analysis of TRPM3 transcripts in GFP-Ki mice 
Western blot analysis suggested the presence of entire and functional TRPM3 proteins in 
pituitaries of GFP-Ki mice but their absence in the choroid plexus. Most likely, this could be 
explained by alternative splicing of TRPM3 transcripts in these tissues. Therefore, I analyzed 
TRPM3 transcripts in total RNA from these tissues of five homozygous GFP-Ki mice by RT-
PCR (Figure  5-12). I used primer combinations that allowed the detection of three different 
splicing scenarios as shown in Figure  5-12, A.  
PCR confirmed different processing of TRPM3 transcripts in pituitary and choroid plexus 
from the very same mice (Figure  5-12, B). From pituitary RNA but not from choroid plexus 
RNA, I obtained fragments matching in size to transcripts with fused exon 24 to exon 25 
using primer combination PH521/PH522 and PH777/PH778. This indicates the preservation 
of the TRPM3 reading frame leading to functional TRPM3 proteins. This finding is in line with 
the detection of TRPM3 proteins of similar size in GFP-Ki pituitaries (Figure  5-11) and I could 
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confirm the presence of TRPM3-mediated Ca2+ entry pathways in Ca2+ imaging experiments 
using the fluorescent Ca2+ indicator dye Fura-2 (see  5.4.3). In this scenario the IRES-GFP 
cassette would be spliced out and would serve as an independent molecule for translation of 
GFP.  
The opposite was true for primer combination PH521/C5-139 and PH777/ C5-139. No 
amplification products were obtained with RNA from pituitary gland but from choroid plexus, 
indicating the fusion of exon 24 to the splice acceptor site upstream to the IRES-GFP 
sequence. This conclusion was confirmed by sequencing of the PCR fragments after they 
were cut out of the agarose gel. As shown in Figure  5-12, C, the fusion of exon 24 to the 
IRES-GFP sequence led to an introduction of a stop codon shortly after exon 24 and thereby 
to a truncation of the TRPM3 protein. 
Using primer combinations SM61/C5-139, PH521/SM24 and PH777/ SM24, I also obtained 
PCR products of 307, 403 and 450, respectively. Although, I can’t rule out that these 
amplification products derived from contaminating genomic DNA present in the RNA 
preparations, these data indicate that also unspliced TRPM3 transcripts exist in GFP-Ki 
mice. These transcripts would also lead to non-functional TRPM3 channel proteins, since 
again stop codons present in intron 24 would shorten the reading frame. 
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Figure  5-12: TRPM3 transcripts are differentially spliced in pituitary gland and choroid plexus 
of GFP-Ki mice.  
(A) Structure of the TRPM3-GFP-Ki allele including the 5`-homology, the floxed exon 24, the 3`-
homology, the splice acceptor (SA), the IRES-GFP cassette and the polyadenylation signal (pA). The 
location of the loxP sequences (orange triangles) and FRT sequences (yellow triangles) are also 
indicated. The scenarios of three splicing events are explained and the primers used to identify each 
splice event are indicated by arrows and names. The table shows the expected length of the 
fragments obtained with the indicated primer combinations. (B) Gel electrophoretic separation of the 
PCR products obtained from mouse pituitary gland and choroid plexus of GFP-Ki mice using primers 
indicated in A. Amplification products labelled with rectangles were purified and sequenced. (C) 
Sequence of the amplification products obtained with primer combination PH777/PH778 from pituitary 
and PH777/C5-139 from choroid plexus with primer sequences and TRPM3 reading frame indicated. 
Sequence sections belonging to exon 24, exon 25, the splice acceptor sequence left after fusion to 
exon 24 and the IRES-GFP cassette are highlighted in colors. Note the stop codon in the TRPM3 
reading frame when the IRES-GFP cassette is fused to exon 24. 
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5.3.1.4 Microscopic detection of GFP fluorescence in native tissues of GFP-Ki 
mice 
I analyzed the presence of fluorescent GFP proteins in native tissues of GFP-Ki mice. 
Pituitary glands and choroid plexus of the brain were dissected and placed immediately in 
ice-cold PBS. The pituitary gland was opened up between anterior lobe (AL) and 
intermediate lobe/posterior lobe (IL/PL). Tissues prepared from WT mice served as negative 
controls. Microscopic analysis of the epifluorescence revealed expression of GFP in the 
choroid plexus and IL/PL of the pituitary gland of GFP-Ki mice which was absent in tissues of 
WT mice (Figure  5-13). This result confirmed that GFP is expressed in choroid plexus and 
pituitary gland of GFP-Ki mice and indicate the presence of native GFP proteins in vital cells 
of whole mount tissue preparations. 
 
Figure  5-13: Expression of GFP in the pituitary gland and choroid plexus of GFP-Ki mice.  
Bright field (upper panel), fluorescence (middle panel) and merged (lower panel) photographs of whole 
mount pituitary gland (left) and choroid plexus (right) isolated from GFP-Ki and WT mice (scale bar = 
100 µm). 
5.3.1.5 Loss of GFP fluorescence after fixation of tissues 
To define the identity of GFP expressing cells in tissues, I had to use cell type-specific 
antibodies for immunostaining. To prevent the degradation of their target epitopes and to 
allow their access into the cells, fixation and permeabilization of the tissues were necessary. 
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However, this procedure has been described to affect the fluorescence intensity emitted by 
GFP [180]. Therefore, I analyzed the GFP fluorescence after removal of fresh tissues 
prepared from GFP-Ki mice and overnight post-fixation in 4 % PFA/PBS. As shown in 
Figure  5-14, GFP fluorescence was still detectable in the choroid plexus of the brain but was 
largely reduced in slices prepared from the pituitary, indicating that the fluorescence intensity 
of GFP expressed in GFP-Ki mice is not sufficient to determine the identity of TRPM3 cells in 
the pituitary gland.  
 
Figure  5-14: Reduction of GFP fluorescence in post-fixed slices of the brain and pituitary gland.  
GFP fluorescence, nucleus staining with Hoechst3342 (Hoechst) and merge image of slices obtained 
from brain and pituitary. Anterior lobe (AL), intermediate lobe (IL) and posterior lobe (PL) regions are 
indicated (scale bar =100 µm).   
I analyzed this effect in more detail using HEK293 cells transiently expressing recombinant 
GFP. 48 h after transfection of the GFP encoding plasmid pCAGGSM2-IRESGFP, cells were 
fixed with different concentrations of PFA and the GFP fluorescence was compared to 
unfixed cells (Figure  5-15). Using imageJ software, the fluorescence intensities of 7-10 cells 
from five different figures were quantified. In line with my observation, that pituitaries showed 
only week GFP fluorescence after fixation with PFA (Figure  5-13), I noticed a concentration-
dependent decrease of fluorescence intensity. Fixation with 4 % PFA reduced the GFP 
fluorescence by 62.7 %.   
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Figure  5-15: Reduction of GFP fluorescence in transfected HEK293 cells after fixation with 
different PFA concentrations. 
Signal intensities of GFP in unfixed HEK cells and after fixation with different concentrations of PFA 
are indicated in each image. Scale bar =100 µm 
In order to visualize green fluorescent proteins as a molecular marker of TRPM3 expression 
and to increase fluorescence associated with GFP, I introduced in the following experiments 
Alexa Flour 488- or Alexa Flour 594 labelled anti-GFP antibodies. Control slices excluding 
anti-GFP antibodies were always included and are shown exemplarily in Figure  5-18. In 
these controls, I never observed signals different from the background. 
5.3.2 Identification of TRPM3 expressing cells of GFP-Ki mice using anti-GFP 
antibodies 
In the previous chapter  5.3.1, I could demonstrate that GFP-Ki mice provide a suitable model 
with GFP as a reporter protein to analyze the expression pattern of TRPM3. 
5.3.2.1 Overview of GFP expression in the whole pituitary  
In an initial series of experiments, pituitary glands were dissected from PFA-perfused GFP-Ki 
and WT mice and 14 µm sections were prepared from. Rabbit polyclonal anti-GFP antibodies 
(anti-GFP) were used in a dilution of 1:5000 to detect GFP proteins in pituitary glands of 
GFP-Ki mice. Anti-LH antibodies (anti-LH) were used to stain gonadotropic cells of the 
anterior pituitary. Staining with anti-GFP antibodies revealed prominent GFP expression in 
the posterior lobe (PL), weaker expression in the intermediate lobe (IL) as well as expression 
in single cells of the anterior lobe (AL, Figure  5-16). The signal obtained with anti-GFP 
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antibodies did not match to the signal of anti-LH antibodies indicating that TRPM3 is not 
expressed in gonadotrophs. 
This experiment revealed the expression of GFP in all three lobes of the pituitary gland of 
GFP-Ki mice and therefore, this expression was analyzed in more details in the following 
experiments. 
 
Figure  5-16: Distribution of immunoreactivity to GFP as an indicatior of TRPM3 expression in 
the anterior (AL), intermediate (IL) and posterior lobe (PL) of pituitary glands from GFP-Ki mice.  
Fluorescence image of 14 µm pituitary sections prepared from GFP-Ki mice stained with anti-GFP 
antibodies (green), anti-LH antibodies (red) (left figure) and Hoechst 33258 for nucleus staining (blue,  
right figure). The insets show fluorescence images of pituitary sections prepared from WT mice which 
served as controls. Scale bar = 200 µm. 
5.3.2.2 Analysis of TRPM3 expression in the posterior lobe 
5.3.2.2.1 TRPM3 proteins are absent in vasopressin or oxytocin-releasing nerve 
terminals. 
The posterior lobe of the pituitary consists in principle of four different elements including VP-
releasing nerve terminals, OXT-releasing nerve terminals, non-secretory nerve terminals and 
specialized glial cells called pituicytes. As the staining using anti-GFP antibodies displayed 
prominent GFP expression in this region, different co-staining experiments were performed 
to identify TRPM3 expressing cells. Oxytocin and vasopressin and their carrier molecules 
neurophysin I and neurophysin II, respectively are all synthesized in the cell bodies of the 
magnocellular neurons (MCNs) of the hypothalamus and released in the posterior pituitary 
from nerve terminals. To investigate the expression of TRPM3 in these nerve terminals, 
14 µm pituitary slices were stained with both anti-GFP antibodies and mixture of anti-
neurophysin I and anti-neurophysin II antibodies (anti-neurophysins). The staining showed 
no co-localization of the fluorescence of anti-GFP antibodies and anti-neurophysins 
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antibodies indicating the absence of TRPM3 protein in the VP- or OXT-releasing nerve 
terminals (Figure  5-17). 
 
Figure  5-17: Distribution of immunoreactivity to GFP and neurophysins I and II in the posterior 
lobe of GFP-Ki and WT pituitaries.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (red), anti-neurophysins (green) and Hoechst 33258 (blue) for nucleus staining. Overlay of 
GFP and neurophysins staining is shown in the right merged image. Scale bar = 20 µm. 
Next, I analyzed whether TRPM3 proteins are expressed in hypothalamic-non-
neurosecretory axons that are also known to terminate in the posterior lobe (Figure  5-18).  
 
Figure  5-18: Distribution of immunoreactivity to GFP and synapsin in the posterior lobe of GFP-
Ki and WT pituitaries.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (green), anti- synapsin (red) and Hoechst 33258 (blue) for nucleus staining. Overlay of GFP 
and synapsin staining is shown in the right merged image. Photographs of control slices excluding the 
primary anti-GFP antibodies (no anti-GFP) were taken using the same exposure time and the same 
filter set as used for the detection of Alexa 488-coupled anti-GFP antibodies. Scale bar = 20 µm.  
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The staining was performed using both anti-GFP antibodies and antibodies directed against 
the synaptic vesicle associated protein synapsin I (anti-synapsin) which is expressed in the 
synaptoid contact with pituicytes [181]. Again, the staining showed no co-localization of 
signals obtained with anti-GFP antibodies and anti-synapsin I antibodies indicating the 
absence of TRPM3 proteins expression in non-neurosecretory nerve terminals of the 
posterior lobe (Figure  5-18).  
5.3.2.2.2 TRPM3 proteins are expressed in pituicytes of the posterior lobe   
Pituitary glial cells or pituicytes are known to express different astroglial markers like GLAST, 
GFAP and S100B. To investigate TRPM3 expression in the pituicytes, GFP-Ki and WT 
pituitary slices were stained using both anti-GFP antibodies in a dilution of 1:5000 and 
phycoerythrin-conjugated anti-GLAST antibodies in a dilution of 1:20 (Figure  5-19). The 
staining showed clear co-localization of signals derived from anti-GLAST antibodies and anti-
GFP antibodies indicating that TRPM3 proteins are expressed in pituicytes. However, in the 
merged image obtained with anti-GFP and anti-GLAST antibodies, I found no complete 
overlap of signals and a spectrum of coloration, probably due to differences of the intensities 
of each immune reaction.  
 
Figure  5-19: Expression of GFP and GLAST-positive cells of the posterior lobe.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (green), anti-GLAST (red) and Hoechst 33258 (blue). Overlay of GFP and GLAST staining is 
shown in the merged image. Scale bar = 20 µm. The very right panels show single pituicytes in higher 
magnification (scale bar = 4 µm) highlighted by rectangles in the merged image.   
Therefore, additional experiments were performed using anti-GFP and anti-GFAP antibodies 
(anti-GFAP). As shown in Figure  5-20, the staining revealed co-localization of signals derived 
from both antibodies confirming TRPM3 expression in pituicytes (Figure  5-20). However, not 
all GFP positive cells were stained with anti-GFAP antibodies, which may rely on the 
presence of different subtypes of pituicytes expressing GFAP [182]. S100B is an acidic, glial-
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specific, calcium binding protein known to be expressed in all pituicytes of the 
neurohypophysis. Anti-S100B antibodies (anti-S100B) were used to label pituicytes in GFP-
Ki and WT pituitary slices. All cells which showed GFP-positive signals were also positive to 
S100B (Figure  5-21) confirming the expression of TRPM3 proteins in pituicytes. In summary, 
using three different pituicytes marker proteins all showed co-localization with GFP, 
demonstrating that TRPM3 is expressed in pituicytes.  
 
Figure  5-20: Co-staining of GFP and GFAP in pituicytes of the posterior lobe.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki mice and WT and stained with 
anti-GFP (red), anti- GFAP (green) and Hoechst 33258 (blue). Overlay of GFP and GFAP staining is 
shown in the right merged image. Scale bar = 100 µm. 
 
Figure  5-21: Co-staining of GFP and S100B in pituicytes of the posterior lobe.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice stained with 
anti-GFP (green), anti-S100B (red) and Hoechst 33258 (blue). Overlay of GFP and S100b staining is 
shown in the right merged image. Scale bar = 100 µm. 
The presence of TRPM3 proteins in the pituicytes was further supported by co-staining of 
slices from WT pituitary with anti-TRPM3 antibodies AK695 and phycoerythrin-conjugated 
anti-GLAST conjugated antibodies. The signals of both antibodies again co-localized in all 
Results  
 
 
 
74 
pituicytes but not in the presence of the antigenic peptide P873, confirming the expression of 
TRPM3 proteins in these cells (Figure  5-22). 
 
Figure  5-22: Immunoreactivity to anti-TRPM3 AK 695 and anti-GLAST antibodies in the 
posterior pituitary gland.  
Fluorescence images of 14 µm pituitary sections prepared from WT mice and stained with AK695 
(alone or after preincubation with a 10000-fold molar excess of peptide P873, green), anti-GLAST 
(red) and Hoechst 33258 (blue). Overlay of AK 695 and GLAST staining is shown in the right merged 
image. Scale bar = 50 µm. 
5.3.2.3 Analysis of TRPM3 expression in the anterior lobe 
The anterior lobe of the pituitary gland consists of five different endocrine cells including 
gonadotrophs, somatotrophs, thyrotrophs, corticotrophs and lactotrophs [1]. In addition to the 
endocrine cells, agranular star-shaped cells called folliculostellate (FS) cells were shown to 
be present in the anterior lobe [1]. As shown above ( 5.3.2.1), GFP expression in the pituitary 
of TRPM3 GFP-Ki mice revealed the presence of TRPM3 proteins in single cells of the 
anterior lobe. The following chapter describes a series of experiments to identify TRPM3 
expressing cells in the adenohypophysis.  
5.3.2.3.1 TRPM3 proteins are absent in endocrine cells of the adenohypophysis 
To analyze the expression of TRPM3 proteins in gonadotrophs, 14 µm pituitary sections from 
WT and GFP-Ki mice were co-stained with antibodies directed against GFP and both 
gonadotropins LH and FSH and GFP proteins. Microscopic analysis of the slices confirmed 
the expression of GFP in the pituitaries of GFP-Ki mice but not of WT mice. Anti-LH and anti-
FSH antibodies (anti-LH/anti-FSH) stained gonadotropic cells in pituitaries of both genotypes. 
In line with the result shown in Figure  5-16, I found no co-staining of GFP and gonadotropins 
indicating the absence of TRPM3 proteins in gonadotrophs (Figure  5-23).  
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Figure  5-23: Distribution of immunoreactivity to GFP and FSH/LH in the anterior lobe of GFP-Ki 
and WT pituitaries.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (green), anti-FSH/LH (red) and Hoechst 33258 (blue). Overlay of GFP and FSH/LH staining 
is shown in the right merged image. Scale bar = 20 µm. 
To investigate the expression of TRPM3 proteins in GH-releasing somatotrophs, pituitary 
slices were co-stained with anti-GFP and anti-GH antibodies (anti-GH). As shown in 
Figure  5-24, the staining showed no co-localization of signals derived from anti-GFP and 
anti-GH antibodies indicating the absence of TRPM3 proteins in the somatotrophs.  
 
Figure  5-24: Distribution of immunoreactivity to GFP and GH in the anterior lobe of GFP-Ki and 
WT pituitaries.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (green), anti-GH (red) and Hoechst 33258 (blue). Overlay of GFP and GH staining is shown 
in the right merged image. Scale bar = 20 µm. 
Similarly, staining of GFP-Ki pituitary slices with anti-GFP antibodies and antibodies directed 
against TSH (anti-TSH, Figure  5-25), ACTH (anti-ACTH, Figure  5-26) or PRL (anti-PRL, 
Figure  5-27) revealed the absence of TRPM3 proteins in the thyrotrophs , corticotrophs or 
lactotrophs, respectively. 
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Figure  5-25: Distribution of immunoreactivity to GFP and TSH in the anterior lobe of GFP-Ki 
and WT pituitaries.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (green), anti-TSH (red) and Hoechst 33258 (blue) for nucleus staining. Overlay of GFP and 
TSH staining is shown in the right merged image. Scale bar = 20 µm. 
 
Figure  5-26: Distribution of immunoreactivity to GFP and ACTH in the anterior lobe of GFP-Ki 
and WT pituitaries.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (green), anti-ACTH (red) and Hoechst 33258 (blue) for nucleus staining. Overlay of GFP and 
ACTH staining is shown in the right image. Scale bar = 20 µm. 
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Figure  5-27: Distribution of immunoreactivity to GFP and PRL in the anterior lobe of GFP-Ki 
and WT pituitaries.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (green), anti-PRL (red) and Hoechst 33258 (blue). Overlay of GFP and PRL staining is 
shown in the right merged image. Scale bar = 20 µm. 
5.3.2.3.2 TRPM3 proteins are expressed in folliculostellate cells of the 
adenohypophysis 
The result that TRPM3 proteins were not detected in any type of endocrine cells ( 5.3.2.3.1) 
and the fact that folliculostellate cells are the only remaining cell type present in the anterior 
lobe raised the idea that TRPM3 proteins might be expressed in these cells. To prove this 
idea, 14 µm pituitary sections from WT and GFP-Ki mice were stained with antibodies 
directed against glutamate aspartate transporter (GLAST) and anti-GFP antibodies 
(Figure  5-28). Staining with anti-GLAST antibodies labelled the soma and the processes of 
star-shaped cells. Staining with anti-GFP antibodies showed the labelling of the very same 
cells indicating that TRPM3 proteins are expressed in folliculostellate cells. 
 
Figure  5-28: Expression of GFP in GLAST positive cells of the anterior pituitary.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (green), anti-GLAST (red) and Hoechst 33258 (blue). Overlay of GFP and GLAST staining is 
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shown in the merged image. Scale bar = 20 µm. The very right panel show magnifications (scale bar = 
4 µm) of single cells highlighted by rectangles in the merged image.  
5.3.2.4 Analysis of TRPM3 expression in α-MSH-producing cells of the 
intermediate lobe 
In addition to very rare non-endocrine marginal cells and astrocytes-like cells, the 
intermediate lobe of the pituitary gland consists mainly of one single endocrine cell type: the 
melanotrophs. Staining of pituitary slices from wild type mice using anti-TRPM3 antibodies 
( 5.2.2) as well as analysis of GFP expression in pituitary slices from GFP-Ki mice already 
revealed the presence TRPM3 in the main fraction of intermediate lobe cells, suggesting the 
presence of TRPM3 in melanotrophs. Melanotrophs release mainly α-melanocyte stimulating 
hormones (α-MSH) which stimulate the melanocytes to produce melanin. To analyse the 
expression of TRPM3 proteins in melanotrophs of the intermediate lobe, 14 µm pituitary 
sections from WT and GFP-Ki mice were stained with antibodies directed against α-MSH 
(anti- α-MSH) and GFP. Anti-α-MSH antibodies stained most cells of the intermediate lobe of 
both WT and GFP-Ki pituitaries. The slices also showed faint signals of GFP staining in 
melanotrophs from GFP-Ki mice that were absent in slices obtained from WT mice indicating 
the expression of TRPM3 proteins in melanotrophs. However, the GFP signals were weak in 
comparison to signals obtained from PL (pituicytes,  5.3.2.2.2), which may be related to lower 
stability of GFP proteins or lower activity of the TRPM3 promoter(s) in these cells.  
 
Figure  5-29: Expression of GFP in α-MSH expressing cells of the intermediate lobe.  
Fluorescence images of 14 µm pituitary sections prepared from GFP-Ki and WT mice and stained with 
anti-GFP (green), anti-α-MSH (red) and Hoechst 33258 (blue). Overlay of GFP and α-MSH staining is 
shown in the right merged image. Scale bar = 100 µm 
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Co-staining of slices from wild type mice using anti-TRPM3 and anti- α-MSH antibodies was 
prevented by the fact that both antibodies were raised in rabbits. However, parallel staining 
of slices obtained from the very same mouse (Figure  5-9) showed strong staining of the 
intermediate lobe again supporting the finding that TRPM3 is expressed in melanotrophs. 
 
Figure  5-30: Distribution of immunoreactivity to α-MSH, LH and TRPM3 in the pituitary gland of 
a wild type mouse.  
The upper panel show fluorescence images of 14 µm pituitary sections from WT stained with anti-α-
MSH (green), anti-LH (red) and Hoechst 33258 (blue). An overlay of α-MSH and α-LH stainings is 
shown in the right merged image. The middle and the lower panels show fluorescence images of 14 
µm sections of the same pituitary stained in parallel with AK695 in the absence or presence of peptide 
P873 (green), anti- LH (red) and Hoechst 33258 (blue). Overlays of AK695 and α-LH staining are 
shown on the right. Scale bars = 100 µm.  
5.4 Analysis of Pregnenolone Sulfate (PregS)-induced Ca2+ signals in 
pituitary cells 
In the latter section ( 5.3), immunohistochemical experiments indicated the expression of 
TRPM3 proteins in folliculostellate cells of the anterior lobe, pituicytes from the posterior lobe 
and finally melanotrophs of the intermediate lobe. In the following section, I investigated the 
functional role of TRPM3 channels in pituitary cells. TRPM3 proteins form Ca2+-permeable 
cation channels in the plasma membrane that are activated by the neurosteroid 
pregnenolone sulfate (PregS, [115]) and efficiently blocked by flavonones like Hesperetin 
[168]. I analyzed the function of TRPM3 channels in pituitary cells in Ca2+ imaging 
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experiments using the fluorescent Ca2+ dye Fura-2. I recorded the changes of the 
intracellular Ca2+ concentration [Ca2+]i upon application of specific ligands of TRPM3: the 
agonist PregS and the antagonist Hesperetin. Reactivity of cells to a combination of both 
ligands was defined as the pharmacological fingerprint of TRPM3 and served as an indicator 
for the presence of functional TRPM3 ion channels in primary cells.  
5.4.1 PregS-induced Ca2+ signals in cells of the anterior lobe  
The anterior lobe consist of at least six different cell populations and the folliculostellate cells 
account for ~ 10 % of the anterior lobe cells [1]. I analyzed TRPM3 channel activity in 
anterior lobe cells of wild type mice (WT) which were compared to control cells from TRPM3-
deficient mice (KO). The anterior lobe was dissected from the intermediate/posterior lobe and 
the cells were prepared as described ( 4.1.1.2). The cells were loaded with 5 µM Fura-2 AM 
at 5 % CO2, 37°C in the dark for 30 min. The measurements were started by perfusion of 
Ringer solution for 75 s followed by perfusion of a saturating concentration of 100 µM PregS 
[115] for 300 s. Finally, a concentration high enough to completely block TRPM3 channels of 
10 µM Hesperetin was added (Figure  5-31). The application of PregS evoked an increase of 
[Ca2+]i in 292 cells from WT mice (Figure  5-31, A and B) whereas the rest of the cells ( 1101) 
did not respond. However, in the responding cell population, I observed three different types 
of responders. 221 cells (15.9 %) also responded to Hesperetin with a clear decrease of the 
[Ca2+]i. These cells displayed the pharmacological fingerprint of recombinant TRPM3 
channels and are therefore defined as TRPM3 expressing cells. In addition to the 
PregS/Hesperetin-sensitive population, 33 cells were insensitive to the application of 
Hesperetin and are therefore not considered to express TRPM3 channels. Finally, another 
minor population of 38 cells showed only a transient response to PregS (Figure  5-31) which 
declined to steady-state levels before Hesperetin has been applied. These cells may still 
express TRPM3 channels but may also respond to PregS because of other PregS-sensitive 
channels like TRPA1 [183]. In contrast to WT cells isolated from the anterior lobe of TRPM3-
KO mice were lacking the population sensitive to both PregS and Hesperetin, whereas 
transient responders and Hesperetin insensitive cells were still detectable (Figure  5-31). 
These findings confirm the presence of functionally active TRPM3 ion channels in ~ 15 % of 
the anterior lobe cells. 
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Figure  5-31: Ca2+ imaging of anterior lobe cells.  
(A) Exemplary measurements of anterior lobe cells prepared from wild type (WT, upper panel) or 
TRPM3-deficient mice (KO, lower panel) in the presence of Ringer solution, during application of 
100 µM pregnenolone sulfate (PregS) and 10 µM Hesperetin. Single traces each belonging to one 
type of responding cell is highlighted in red, dark gray, light gray and blue. (B) Mean values (± S.E.M) 
of experiments as shown in (A). The numbers of cells of each cell population/the total number of cells, 
as well as the number (n) of measurements/experiments are indicated. Note that cells responding to 
both PregS and Hesperetin are missing in cells prepared from TRPM3-deficient mice.  
The presences of PregS-sensitive Ca2+ entry pathways in anterior lobe cells unrelated to 
TRPM3 channels were further analyzed. Cells were pre-incubated with TRPM3 blocker 
Hesperetin before PregS was applied (Figure  5-32). This treatment was expected to block 
PregS-induced TRPM3-mediated Ca2+ influx while TRPM3-unrelated Ca2+ entry pathways 
remain unaffected. Figure  5-32 shows that PregS induced a comparable increase of [Ca2+]i in 
a similar number of both WT and KO anterior lobe cells confirming the presence of additional 
PregS-sensitive Ca2+ entry mechanisms in anterior lobe cells.  
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Figure  5-32: Presence of PregS-induced Ca2+ entry unrelated to TRPM3 in anterior lobe cells.  
Response to Pregnenolone sulfate (PregS) in anterior pituitary cells from wild type (black) and 
TRPM3-deficient (red) mice after pre-incubation with the TRPM3 blocker Hesperetin. Mean values of 
37 and 44 responding cells ± SEM detected in a total number of 344 and 365 WT and KO cells are 
indicated. The number of measurements (n) is indicated. 
5.4.2 PregS-induced Ca2+ signals in cells of the intermediate/posterior lobe  
Due to the fact that a microscopic separation of the posterior lobe and the intermediate lobe 
was impossible, the cells from these two lobes were prepared and analyzed together in the 
following Ca2+ imaging experiments and patch-clamp recordings. 
5.4.2.1 Immunohistochemical characterization of primary pituitary cells 
obtained from the intermediate and posterior lobe 
First, cells that were prepared as described in ( 4.1.1.2), were characterized 
immunohistochemically. Cells were co-stained with anti-α-MSH antibodies, anti-GFAP 
antibodies and Hoechst 33258 for staining of the nucleus. As shown in Figure  5-33, I found 
two main populations of cells: 1. α-MSH-positive and GFAP-negative round-shaped cells 
which were thought to represent melanotrophs derived from the intermediate lobe and 2. α-
MSH-negative and GFAP-positive cells with irregular shape thought to represent pituicytes 
derived from the posterior lobe. 
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Figure  5-33: Characterization of primary cells obtained from the intermediate/posterior lobe.  
Single primary cells from the IL/PL in a bright field microscopic image (upper left) and fluorescence 
images of the same cells after staining with anti-α-MSH (red), anti-GFAP staining (green) antibodies 
and Hoechst 33258 (blue) are shown. Merged images of fluorescence stainings (lower middle) and of 
all images (lower right) are also presented. Round cells are highlighted by white arrows, flat cells by 
black arrows. Additional nuclei which may belong to dead cells (see merged image) were also 
detectable. Scale bar = 100 µm. 
5.4.2.2 Identification of PregS-sensitive Ca2+ entry pathways in cells of the 
intermediate/posterior lobe 
Next, I analyzed in Ca2+ imaging experiments whether Ca2+ entry pathways which can be 
activated by PregS exist in cells of the intermediate/posterior lobe (IL/PL). Using the same 
protocol as described in the previous section ( 5.4.1), I found within a total number of 179 
cells, 61 cells that responded to the application of PregS (Figure  5-34). Within this population 
of responders, I identified again three subpopulations. The PregS induced increase of [Ca2+]i 
in 44 cells was sensitive and effectively blocked by Hesperetin. These cells are therefore 
defined as TRPM3 expressing cells, which represent 24.5 % of the total number of cells. 
Cells sensitive to both PregS and Hesperetin were missing in cell population from TRPM3-
deficient (KO) mice (Figure  5-34) confirming this definition. Similar to anterior lobe cell 
preparations, I also found in WT cell preparations, few cells (6/179) which were insensitive to 
the application of Hesperetin or which responded only transiently to PregS (11/179). These 
cells were not expected to express TRPM3 but may contain other PregS-sensitive Ca2+ entry 
pathways. Consistent with this idea, these cells were also detectable in cell preparations of 
TRPM3-deficient mice (Figure  5-34, lower panel and Figure  5-35). 
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In summary, these experiments demonstrated that in addition to other Ca2+ entry pathways, 
TRPM3 ion channels allow the influx of Ca2+ into pituitary cells derived from the 
intermediate/posterior lobe. 
 
Figure  5-34: Ca2+ imaging of intermediate/ posterior (IL/PL) lobe cells.  
(A) Exemplary measurements of intermediate/ posterior lobe cells prepared from wild type (WT, upper 
panel) or TRPM3-deficient mice (KO, lower panel) in the presence of Ringer solution, during 
application of 100 µM pregnenolone sulfate (PregS) and 10 µM Hesperetin. Single traces each 
belonging to one type of responding cell is highlighted in red, dark gray, light gray and blue. (B) Mean 
values (± S.E.M) of experiments as shown in (A). The number of cells of each cell population/the total 
number of cells, as well as the number (n) of measurements/experiments is indicated. Note that cells 
responding to both PregS and Hesperetin are missing in cells prepared from TRPM3-deficient mice. 
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Figure  5-35: Presence of PregS-induced Ca2+ entry unrelated to TRPM3 in intermediate 
/posterior lobe cells.  
Response to Pregnenolone sulfate (PregS) in PL/IL cells from wild type (black) and TRPM3-deficient 
(KO) mice after pre-incubation with the TRPM3 blocker Hesperetin. Mean values of 12 and 6 
responding cells ± SEM detected in a total number of 110 and 80 WT and KO cells are shown, 
respectively. The number of measurements (n) is indicated. 
5.4.2.3 Identification of TRPM3-mediated Ca2+ entry pathways in melanotrophs 
of the intermediate lobe 
In order to determine the identity of PregS/Hesperetin-sensitive cells in the mixed cell 
preparation ( 5.4.2.2), cells derived from IL/PL were plated onto grid coverslips (BELLCO 
Biotechnology, USA) and analyzed in Ca2+-imaging experiments (Figure  5-36). Subsequent 
to the measurement, cells were fixed, permeabilized, and stained with anti α-MSH 
antibodies. The grid on the coverslips allowed the identification of those cells which 
responded to PregS and Hesperetin. I found that 95.8 % of the responders (46/48) were 
stained with anti-α-MSH antibodies, whereas no other cells were stained. This experiment 
provided strong evidence that melanotrophs of the intermediate lobe express active TRPM3 
ion channels.  
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Figure  5-36: α-MSH expressing cells display TRPM3-mediated Ca2+ signals.  
(A) Cells prepared from the IL/PL were analyzed in Ringer solution, during application of 100 µM 
pregnenolone sulfate (PregS) and 10 µM Hesperetin. Ca2+ signals of 48 cells responding to 
PregS/Hesperetin (red traces) and their mean ± SEM (black trace) are shown. Non responding cells 
(69) are not displayed. (B) Merge of a bright field image to visualize the grid on the coverslip, a 
fluorescence image demonstrating immunoreactivity to α-MSH antibodies (red) and Hoechst 33258 
(blue) staining of the cell nuclei. 
5.4.2.4 Isolated melanotrophs but not pituicytes display PregS-inducible Ca2+ 
signals  
In the preceding section, I could show that α-MSH expressing cells display Ca2+ signals that 
are sensitive to PregS and Hesperetin and are therefore likely to contain active TRPM3 
channels. However, only α-MSH-positive cells but not other cells were stained. This raised 
the question, whether pituicytes which also express TRPM3 transcripts (Figure  5-5, 
Figure  5-6) and TRPM3 proteins ( 5.3.2.2.2) contain active TRPM3 channels. To address this 
question, I chose an alternative approach. Cells prepared from the IL/PL were stained with 
anti-GLAST antibodies and were separated by fluorescence-activated cell sorting (FACS). 
Staining with anti-GLAST antibodies (GLAST-positive cells) was attributed to pituicytes, 
whereas the absence of immunoreactivity to these antibodies (GLAST-negative cells) was 
attributed to melanotrophs. The cells were sorted onto poly-L-lysine covered coverslips for 
functional and morphological analysis. In addition, 50 GLAST-positive or GLAST-negative 
cells were sorted into tubes for analysis of TRPM3 expression by PCR (see  5.1.4). 
To allow recovery of cells after sorting, Ca2+ imaging experiments were performed as 
described ( 5.4.1) 24 h after the sorting procedure. After loading of the cells with Fura-2, 
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morphological differences were analyzed microscopically (Figure  5-37, A). GLAST-positive 
cells (pituicytes) looked bigger in size and more flat with processes and extensions whereas 
GLAST-negative cells were smaller with a round shape (Figure  5-37, A). While all GLAST-
negative cells (5) showed clear response to the application of both PregS and Hesperetin, 
GLAST-positive cells did not respond to the application of 100 µM PregS (Figure  5-37, C and 
B, respectively). This result again demonstrated the presence of functional TRPM3 channels 
in melanotrophs (GLAST-negative cells) and also confirmed their absence in pituicytes 
although these cells express TRPM3 transcripts and proteins. The absence of functional 
TRPM3 proteins function in pituicytes was proved by additional experiment using the patch-
clamp technique ( 5.5). 
 
Figure  5-37: Morphological and functional analysis of sorted posterior/intermediate lobe cells. 
(A) A microscopic view of Fura-2 AM loaded GLAST-negative cells (left) and GLAST-positive cells 
(right). (B) GLAST-negative cells were analyzed in Ringer solution, during application of 100 µM 
pregnenolone sulfate (PregS) and 10 µM Hesperetin. Ca2+ signals of 5 cells responding to 
PregS/Hesperetin (colored traces) and their mean ± SEM (red trace) are shown. (C) GLAST-positive 
cells were analyzed similarly and displayed no response to PregS. Single cells are shown in colored 
traces and their mean ± SEM as gray trace.   
5.4.2.5 Long-term culture of pituicytes did not recover TRPM3 activity 
The absence of Ca2+ entry into pituicytes after PregS stimulation might be related to the 
preparation of cells and their culture conditions. Therefore, I tested whether primary “explant” 
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cultures of pituicytes displayed PregS-inducible Ca2+ entry. For that purpose, explant cultures 
were prepared as described ([172],  4.1.1.2). The cells proliferated and grew for period of at 
least 12 days. After this time, cells were fixed and stained either with anti-GFAP or anti-
S100B antibodies providing evidence of their identity (Figure  5-38, A). Furthermore, I 
performed Ca2+ imaging experiments. Cells were loaded with Fura-2, but again after addition 
of 100 µM PregS, the cells did not display any change in the intracellular Ca2+ concentration 
(Figure  5-38, B). This experiment demonstrated that living and proliferating pituicytes do not 
respond to PregS albeit they may express TRPM3 proteins. 
 
Figure  5-38: Properties of long-term cultures of pituicytes. 
(A) Fluorescence images of explant pituicytes cultures stained with anti-GFAP antibodies (left image) 
or with anti-S100B antibodies (right image) and Hoechst 33258  (scale bar = 100 µm) (B) Cells were 
analyzed in Ca2+ imaging experiments in Ringer solution, during application of 100 µM pregnenolone 
sulfate (PregS) and 10 µM Hesperetin. The mean ± SEM of 55 cells is shown.  
5.4.3 TRPM3-mediated Ca2+ entry is preserved in TRPM3-GFP-Ki mice 
The targeting strategy to generate GFP-Ki mice included the fusion of exon 24 to the splice 
acceptor site of the IRES-GFP cassette which would lead to a frame shift of the TRPM3 
reading frame and a premature stop of translation. However, I observed in the pituitaries of 
mice homozygous for the L3F1 (GFP-Ki) allele that long TRPM3 proteins similar in size to 
the recombinant TRPM3α2 proteins are still expressed ( 5.3.1.2). Consisting with that finding, 
PCR analysis revealed splicing of exon 24 to exon 25, preserving the TRPM3 reading frame 
( 5.3.1.3). Therefore, I tested in Ca2+ imaging experiments whether active TRPM3 channels 
are still present in pituitary cells (Figure  5-39). Cells from the anterior lobe and from the 
intermediate/posterior lobe of TRPM3GFP-Ki/GFP-Ki mice both showed a reliable number of cells 
which displayed PregS-induced Ca2+ entry which was blocked by the addition of Hesperetin. 
This finding demonstrates that active TRPM3 channels are present in the pituitary of GFP-Ki 
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mice. Although the IRES-GFP cassette is spliced out from the primary TRPM3 transcript 
(Figure  5-12), the cells express in addition to TRPM3 the GFP protein.  
 
Figure  5-39: Ca2+ imaging of pituitary cells from mice homozygous for the L3F1 allele 
(TRPM3GFP-Ki/GFP-Ki).  
Ca2+ signals in anterior lobe cells (A) and intermediate/posterior lobe cells (B) from GFP-Ki mice in the 
presence of Ringer solution, during application of 100 µM pregnenolone sulfate (PregS) and 10 µM 
Hesperetin. Mean values ± SEM are displayed of 54 and 69 cells detected in 756 and 134 anterior and 
intermediate/posterior lobe cells, respectively. The number of measurements (n) is indicated. 
5.5 Analysis of ionic currents in pituitary cells of the intermediate and 
the posterior lobe (Dr. Beck) 
The results of the preceding chapters provided strong evidence that TRPM3 proteins are 
expressed in melanotrophs of the intermediate lobe ( 5.3.2.4), and pituicytes of the posterior 
lobe ( 5.3.2.2.2). However, Fura-2 measurements of the IL/PL cell preparations indicated that 
only round and smooth cells that were stained with anti-α-MSH antibodies responded to 
PregS and Hesperetin ( 5.4.2), whereas sorted flat and irregular pituicytes which were stained 
with anti-GLAST antibodies did not (Figure  5-37). In the following chapter, we characterized 
the biophysical properties of ionic currents of these two cell populations by whole-cell patch-
clamp recordings. The electrophysiological experiments were kindly performed by Dr. 
Andreas Beck. 
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5.5.1 Characterization of voltage-gated ionic currents in IL/PL cell 
preparations 
In the culture of primary intermediate and posterior lobe cells, the only endocrine cells were 
the melanotrophs (Figure  5-33), which has been shown to express different types of voltage-
activated sodium channels [3].  
To characterize the primary cells electrophysiologically and to distinguish melanotrophs and 
pituicytes not only by their morphology, but also by their biophysical properties, voltage 
ramps from -100 to +100 mV over 50 ms duration were applied in the whole-cell 
configuration at 0.5 Hz starting from a holding potential (Vh) of -80 mV (Figure  5-40). 
Round cells (Figure  5-40, A) displayed voltage-dependent inward currents when the cells 
were depolarized to ~ -40 mV which inactivated at a membrane potential of ~ -10 mV 
(Figure  5-40, B). When the holding potential between the ramps was increased to 0 mV 
these inward currents disappeared (Figure  5-40, C). The current/voltage relationship at 
Vh = -80 mV (Figure  5-40, B) and the absence of the current at Vh = 0 mV (Figure  5-40, C) 
strongly resembled typical features of voltage-gated Na+ channels and confirm the identity of 
these cells as melanotrophs. In contrast, application of the same protocol to the irregular-
shaped cells (Figure  5-40, D) did not reveal any current, indicating the absence of voltage-
gated Na+ channels in these cells (Figure  5-40, E and F).  
To ensure the identity of NaV channels in the round-shaped melanotrops, whole-cell patch-
clamp experiments were performed in the absence of extracellular Na+ (replaced by 140 mM 
N-Methyl-D-glucamin, NMDG). Removal of extracellular Na+ led to a complete 
disappearance of the inward current (Figure  5-41, A) whereas removal of Ca2+ did not 
change the appearance of the voltage-activated inward current (Figure  5-41, B). These 
experiments proof that the voltage-activated inward current seen in the melanotrophs are 
mediated by NaV channels. 
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Figure  5-40: Morphological and electrophysiological properties of posterior and intermediate 
lobe cells.  
Round cells (A) and flat, irregular-shaped cells (D) were patched (whole-cell configuration) and 
currents were measured during the application of voltage ramps from -100 mV to +100 mV within 50 
ms starting from a holding potential (Vh) of -80 mV (B,E), or within 400 ms starting from Vh of 0 mV 
(C,F). Thick traces indicate the mean of the single traces (gray, B, C, and green, E, F). Flat cells 
neither revealed NaV currents at a holding potential of -80 mV (E) nor the outward rectifying current, 
seen in round cells. n indicates the number of measured cells. 
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Figure  5-41: Identity of NaV channels.  
(A) Current-voltage relationships (IVs) of whole-cell currents in round cells measured as described 
before (Figure  5-40, B) in the presence of 140 mM extracellular NaCl (black trace) and after 
replacement of Na+ by 140 mM NMDG (red trace). (B) Current-voltage relationships (IVs) of NaV 
currents in round cells in the presence (black trace) and absence (red trace) of 1 mM extracellular 
Ca2+, both in the presence of extracellular Na+. 
5.5.2 Identification of TRPM3-mediated ionic currents in primary melanotropic 
cells 
Immunohistochemistry ( 5.3.2.4) and PCR-analysis ( 5.1.4) as well as Ca2+-imaging 
experiments of isolated GLAST-negative cells ( 5.4.2.4), revealed the presence of functional 
TRPM3 ion channels in melanotrophs. We confirmed this finding and analyzed the 
biophysiological properties of endogenous TRPM3 channels in the melanotrophs by whole-
cell patch-clamp experiments (Figure  5-42). After break-in into round shaped-cells, NaV 
currents were measured as described in  5.5.1 to identify the cell as melanotroph. 
Subsequently, a voltage ramp protocol was applied as described in Figure  5-40, C and ionic 
currents were challenged by perfusion of 100 µM PregS. As shown in Figure  5-42, strong 
outward currents and small inward currents appeared upon PregS application resembling the 
typical current-voltage (IV) relationship described for TRPM3 channels ([103], Figure  5-42, A, 
B). In addition, the PregS-induced currents were readily inhibited by 10 µM Hesperetin, and 
thus, displayed the pharmacological fingerprint of recombinant TRPM3α2 channels 
[115,118]. Current-voltage relationship and inhibition of the PregS-induced currents by 
Hesperetin strongly indicate the expression of functional TRPM3 channels in these cells. 
Again, flat and irregular-shaped pituicytes did not show any response to PregS (Figure  5-42, 
C, D).  
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Figure  5-42: PregS-induced currents in primary cells of the intermediate/posterior lobe cells of 
the pituitary.  
(A, C) Inward and outward currents at -80 and +80 mV, respectively, measured in melanotrophs (A) 
and pituicytes (C) during the application of 100 µM PregS, and in (A), 10 µM Hesperetin. Basic 
currents right before PregS application were subtracted. B and D depict the respective current-voltage 
relationships (IVs) of the net current induced by 100 µM PregS in melanotrophs (B, single experiments 
in gray and mean in black) and pituicytes (C, single experiments in light green and mean in green). 
Hesperetin inhibited the PregS-induced currents in melanotrophs (A, B). The IVs of the remaining 
currents in A are shown in B (single experiment in light blue and mean in blue). Data represent means 
(± SEM) of the indicated number of experiments (n). 
TRPM1, the closest relative of TRPM3, may also be activated by PregS [109]. To rule out 
any contribution of TRPM1 channels to the PregS-induced currents in melanotrophs, we 
applied 100 µM Zn2+, which has been shown to inhibit TRPM1 but not TRPM3 [109], during 
the presence of the PregS-induced current. As shown in Figure  5-43, we found almost no 
change of the PregS-induced currents in melanotrophs when 100 µM Zn2+ was added. 
Furthermore, TRPM1 transcripts were not detectable in these cells ( 5.1.4).   
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Figure  5-43: PregS-induced currents are not inhibited by zinc ions in melanotropic cells.  
(A) Inward and outward currents measured at -80 and +80 mV, respectively, during application of 100 
µM PregS and 100 µM Zn2+. (B) Current-voltage relationships of the net PregS-induced current (basic 
currents subtracted) before (black) and in the presence of 100 µM Zn2+ (red). Data represent means 
(± SEM) of the indicated number of experiments (n). 
To further proof the identity of the PregS/Hesperetin-sensitive currents in melanotrophs as 
TRPM3-dependent, we isolated melanotrophs from TRPM3-deficient mice (KO, Figure  5-44). 
The whole-cell patch-clamp experiments, revealed no difference in the appearance of the 
voltage-gated Na+ currents in melanotrophs from both genotypes (Figure  5-44, A, D). 
However, in contrast to melanotrophs isolated from wild type mice (Figure  5-44, B, C), 
melanotrophs isolated from TRPM3-deficient mice (Figure  5-44, E, F) did not reveal any 
current upon application of 100 µM PregS.  
This data prove the presence of functional TRPM3 channels in melanotrophic cells of mouse 
pituitary.     
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Figure  5-44: PregS-inducible currents are absent in melanotrophs isolated from TRPM3-
deficient (KO) mice.  
(A, D) Current-voltage relationships (IVs) of NaV currents measured as described in Figure  5-40, B in 
melanotrophs from WT (A) and TRPM3-KO mice (D). (B, E) Inward and outward currents at -80 and 
+80 mV, respectively, measured in WT cells (B) and TRPM3-KO cells (E) during the application of 100 
µM PregS, and 10 µM Hesperetin. (C) and (F) depict the respective current-voltage relationships (IVs) 
of the net measured current (basic currents subtracted) induced by 100 µM PregS in WT cells (B, 
single experiments in gray and mean in black) and TRPM3-KO cells (single experiments in light red 
and mean in red). Hesperetin inhibited the PregS-induced currents in WT cells (B, C). The IVs of the 
remaining current is shown in C (single experiments in light blue and mean in blue). Data represent 
means (± SEM) of the indicated number of experiments (n). The amplitude of the PregS-induced 
currents in WT melanotrophs were slightly smaller than in the experiment shown in (Figure  5-42, A, B). 
This might be due to the different internal solutions used in both experiments. Experiments in 
Figure  5-42 were done using Cs-glutamate in the patch pipette and in the present experiment Cs-
methanosulfonate was used. 
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6 Discussion 
The current work aimed at the identification of TRPM3 proteins in mouse pituitary gland and 
the definition of pituitary cell types expressing these proteins.  
Using GFP-Ki mice and a collection of cell type-specific antibodies, I identified three types of 
cells that express TRPM3 proteins. 
1. Folliculostellate cells of the adenohypophysis which form a signaling network 
connected by gap junctions and which are considered to be non-secretory cells. 
2. Pituicytes, which are glial cells of the neurohypophysis that mainly assist in the 
storage and release of hypothalamic hormones. 
3. Melanotrophs of the intermediate lobe that release α-MSH into the blood. 
I also aimed at the determination of TRPM3-mediated Ca2+-signals and TRPM3 currents in 
pituitary cells in order to elucidate the physiological role of TRPM3 channels in the 
hypophysis. Using a combination of the TRPM3 agonist PregS and the antagonist 
Hesperetin, I dissected TRPM3-mediated Ca2+ signals in cell preparations of both the anterior 
lobe and the intermediate/posterior lobe demonstrating the activity of native TRPM3 
channels in both regions of the hypophysis and confirming the results of the 
immunohistochemical experiments. Finally, characterization of PregS/Hesperetin-sensitive 
currents in primary melanotrophic cells proofed the presence of functional TRPM3 channels. 
6.1 Possible roles of TRPM3 channels in folliculostellate (FS) cells of 
the anterior lobe 
Fura-2 measurement of anterior pituitary cells uncovered Ca2+-signals ( 5.4.1) that were 
activated by PregS and inhibited by Hesperetin. Thus, these cells displayed the 
pharmacological fingerprint of recombinant TRPM3 channels and therefore it is reasonable to 
sugesst that these signals were mediated by TRPM3 channels. 15 % of the cells displayed 
such a phenotype, which is in good agreement with the number of folliculostellate (FS) cells 
described in pituitary gland [1]. This functional observation was strongly supported by my 
immunohistochemical results. First, no hormone secreting cell population within the 
adenohypophysis matched to the GFP-fluorescence observed in pituitaries of GFP-Ki mice. 
Vice versa, glutamate aspartate transporter (GLAST) proteins have been described to be 
expressed on the surface of FS cells [8] and cells stained with anti-GLAST antibodies co-
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stained with anti-GFP antibodies in these mice. Thus, it is reasonable to conclude that 
TRPM3 proteins build Ca2+-permeable ion channels in FS cells. 
FS cells are known to form a three dimensional cell network connected by gap junctions [5]. 
This network was shown to carry Ca2+ waves and other small diffusible molecules over long 
distances in the millimeter range providing a communication system between anterior lobe 
cells. It has been described that the initiation of this Ca2+ waves is dependent on the activity 
of voltage-activated Na+ and Ca2+ channels expressed in these cells [9]. Na+ and Ca2+ influx 
through TRPM3 channels might increase the membrane potential and may facilitate the 
activation of voltage-activated channels. This way TRPM3 channels may contribute to the 
propagation of Ca2+ waves through the FS cell network.  
FS cells influence the release of FSH from gonadotrophs [55,184]. Binding of pituitary 
adenylate cyclase-activating peptide (PACAP) to its receptor on FS cells stimulates 
transcription of the follistatin gene through cyclic adenosine monophosphate/protein kinase A 
(PKA) signaling. TRPM3 might be involved in this process in a hitherto undiscovered 
manner. Since follistatin is known to reduce FSH-release from gonadotrophs of the pituitary, 
TRPM3 might have an indirect regulatory influence upon ovulation [184]. 
Vascular endothelial growth factor (VEGF) is a signal protein that stimulates vasculogenesis 
and angiogenesis and has been implicated as an important factor in tumorigenesis such as 
in mamma carcinoma [185,186]. Therefore, VEGF has been recognized as a drug target to 
treat solid tumors and a number of anti-VEGF antibodies such as bevacizumab and 
ranibizumab have been developed as anti-tumor drugs [186]. The secretion of vascular 
endothelial growth factor (VEGF) from FS cells has been shown to be Ca2+-dependent [187]. 
Ca2+ influx through TRPM3 might trigger the release of VEGF and contribute this way to 
disease development. Agonists of TRPM3 such as Hesperetin and isosakuranetin [118,168] 
may reduce TRPM3-dependent VEGF release from FS cells and may finally represent an 
alternative approach for the treatment of solid tumors. 
6.2 Possible roles of TRPM3 channels in pituicytes of the 
neurohypophysis 
Immunohistochemical analysis of the posterior lobe revealed that neither vasopressin (VP)- 
nor oxytocin (OXT)-releasing nerve terminals matched to GFP staining of the posterior lobe 
indicating that TRPM3 proteins are absent in nerve endings of the neuropituitary.  Pituicytes, 
a subtype of astrocytes in the pituitary gland [188], are known to express GLAST, GFAP and 
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S100B proteins [8,182]. I found that cells stained with anti-GLAST antibodies were co-
stained with anti-GFP antibodies indicating that TRPM3 is expressed in the pituicytes. 
However, the colocalization displayed a spectrum of coloration due to the difference in 
intensity of each immune reaction. Therefore, the identity of these green cells was confirmed 
by co-staining of both GFAP and S100B antibodies. I found that all GFP-positive cells were 
immunoreactive to anti-S100B antibodies. On the other hand, there were cells which were 
GFP-positive but did not show staining with anti-GFAP antibodies. This finding is in good 
agreement with the fact that two types of pituicytes including parenchymatous and fibrous 
pituicytes exist [182]. The parenchymatous pituicytes have been shown to be 
immunoreactive to both anti-GFAP and anti-S100B antibodies but the fibrous pituicytes are 
only immunoreactive to anti-S100B antibodies [182]. In contrast to my immunohistochemical 
results indicating the presence of TRPM3 in pituicytes, these cells did not respond to PregS. 
This unexpected finding was confirmed by three individual approaches:  
1. The posterior/intermediate lobe (PL/IL) and the anterior lobe (AL) could be easily 
separated from each other under the stereomicroscope [189]. However, the 
intermediate lobe was always tightly attached to the posterior lobe and could not be 
removed. Cell preparations of the PL/IL contained mainly two types of cells which 
could be already distinguished by their shape: round cells and flat star-shaped cells 
(Figure  5-37, Figure  5-40). Co-staining with anti-α-MSH and anti-GFAP antibodies 
identified round cells as melanotrophs and flat cells as pituicytes (Figure  5-33). Fura-
2 imaging experiments demonstrated that the round-shaped melanotrophs responded 
to PregS whereas the flat shaped pituicytes did not. The identity of the analyzed cells 
was reconfirmed by staining of the very same cells on a grided coverslip 
(Figure  5-36). 
2. Patch-clamp recordings of the round cells identified Na+-currents mediated by 
voltage-activated NaV channels (Figure  5-40). These channels have already been 
described in melanotrophs [3] confirming that the round cells represent melanotrophs 
and the voltage-gated Na+ currents were taken as independent functional indicator of 
the identity of melanotrophs. Without any exception all NaV-positive cells displayed 
currents in response to PregS that were absent in the presence of Hesperetin 
(Figure  5-42). However, measurements of the flat cells within the preparations did 
never show any response to PregS. 
3. I made use of fluorescence-activated cell sorting (FACS) to separate GLAST-positive 
pituicytes from GLAST-negative cells and analyzed these cells in calcium imaging 
experiments. GLAST-positive cells did not respond to PregS in contrast to GLAST-
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negative cells (Figure  5-37). Thus although pituicytes do express TRPM3, they do not 
respond to PregS. 
The most probable reason for such a behavior was, that the pituicytes did not survive the cell 
preparation process. However, pituicytes (I) immediately responded to a change of the 
extracellular Ca2+ concentration (not shown); (II) showed reasonable low basal currents after 
break-in with the patch pipette (Figure  5-40) and (III) could be kept in culture for 8-12 days 
[48]. In culture, the cells proliferated but still did not respond to PregS (Figure  5-38). Another 
explanation for the lack of a PregS response could be that the TRPM3 isoforms expressed in 
pituicytes form non-functional channels or channels that are impermeable for Ca2+. However, 
PCR analysis of GLAST-positive cells isolated by FACS indicated that the TRPM3 transcripts 
expressed in these cells encode channels with a Ca2+-permeable pore [103] and which do 
not lack the ICF-region that is indispensable for channel function [111].  
Thus it remains an open question, whether functional TRPM3 channels are present in 
pituicytes and how they get activated. There is still an ongoing debate, if PregS is really a 
physiological ligand of TRPM3 channels and additional modulators of TRPM3 activity have 
been identified recently [163]. Perhaps, additional or other stimuli like D-erythrosphingosine 
[161], increased temperature [105] and hypoosmotic extracellular conditions [101] are 
necessary to activate TRPM3 channels in pituicytes and need to be tested in the future. 
Indirect evidence supports the idea that TRPM3 may be involved in one of the key functions 
of pituicytes, which is the regulation of vasopressin and oxytocin release by hypothalamic 
nerve terminals. Under resting conditions, pituicytes form a physical barrier between axon 
terminals and blood vessels thereby reducing hormone availability. Under stress such as 
dehydration or parturition, pituicytes undergo morphological changes and retract from the 
vessels leading to an increased hormone output from the axons into the blood [10,48]. This 
process is called “stellation” and has been studied in vitro using explant cultures of primary 
pituicytes. Adenosine has been found to induce stellation of pituicytes after activation of A1 
adenosine receptors but this process is independent of the intracellular calcium 
concentration since it also happens when [Ca2+]i is buffered with BAPTA [172]. However, 
released vasopressin acts on V1a-vasopressin receptors present on the surface of  pituicytes 
resulting in an increase of  [Ca2+]i  and a subsequent taurine release which acts as a negative 
feedback inhibitor of VP release from the nerve terminals [46,48]. Taurine release from 
pituicytes has also been shown to be induced under hypotonic conditions, but hypotonic 
solutions were not able to evoke calcium signals in the cells [172]. When [Ca2+]i was buffered 
with BAPTA, both the vasopressin and the hypotonicity induced taurine release was blocked. 
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These findings suggest that Ca2+ plays an important role in pathways underlying taurine 
release [48]. TRPM3 channels may coordinate the different stimuli involved in taurine release 
and may only get active under hypotonic conditions after binding of vasopressin to its 
receptors. 
6.3 TRPM3 is expressed in melanotrophs and may contribute to the 
release of α-MSH and other hormones  
In the intermediate lobe of GFP-Ki mice, immunohistochemical staining using anti-GFP 
antibodies and anti-α-MSH antibodies indicated the expression of TRPM3 in α-MSH-
producing melanotrophs (Figure  5-29). The expression of TRPM3 in melanotrophs was 
confirmed using anti-TRPM3 antibodies (AK695) which strongly labelled the whole 
intermediate lobe of the gland similar to anti-α-MSH antibodies (Figure  5-30). Both Fura-2 
measurements and patch-clamp recordings confirmed this finding and demonstrated 
functionally active TRPM3 channels in these cells ( 5.4.2.4,  5.5):  
• Almost all cells which displayed Ca2+ signals in response to PregS and Hesperetin 
were stained with anti-α-MSH antibodies (Figure  5-36).  
• PregS inducible Ca2+-signals that were sensitive to Hesperetin were absent in IL/PL 
cell preparations of TRPM3-deficient mice (Figure  5-34)  
• GLAST-negative cells isolated by FACS showed the typical morphology of 
melanotrophs, responded to both PregS and Hesperetin (Figure  5-37) and contained 
TRPM3 transcripts (Figure  5-5). 
• Round cells prepared from  IL/PL showed both voltage-activated Na+ currents and 
PregS induced currents which displayed a current/voltage relationship (Figure  5-42) 
highly similar to currents through recombinant TRPM3 channels [103]. These currents 
were absent in both the presence of Hesperetin and in cells obtained from TRPM3-
deficient mice.   
Melanotrophs release α-MSH, which fulfills important physiological functions including 
melanogenesis, inflammation, energy homeostasis, appetite regulation and inhibition of food 
intake [35,38,39,190].  POMC precursor peptides undergo proteolytic cleavage resulting in 
the formation of α-MSH, β-endorphin and other regulatory peptides. It has been described 
that gene expression of POMC as well as its cleavage by prohormone convertase are Ca2+-
dependent [191-193]. Furthermore, hormone peptides are packaged in secretory vesicles 
and are released by Ca2+-dependent exocytosis [62]. Ca2+ influx through TRPM3 might be 
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important in one or more of the processing steps of POMC as well as in the release of α-
MSH. 
Outlook  
It would be exciting to investigate the influence of TRPM3 upon α-MSH release eg. by 
enzyme-linked immunosorbent assay (ELISA). One could ask whether the activation of 
TRPM3 with PregS could increase the release of α-MSH. Furthermore, one could compare 
α-MSH release or the amount of α-MSH inside the cell between wild type and TRPM3-
deficient mice. Preliminary data of ELISAs and bead-based immunoassays (not shown) 
indeed indicated that TRPM3 participates in the production and/or the release α-MSH from 
primary melanotrophs. The amount of α-MSH was increased in the supernatant of PregS-
treated cells but not in the presence of Hesperetin. Furthermore, the α-MSH concentrations 
in the supernatant of melanotrophs prepared from TRPM3-deficient mice (KO) was strongly 
reduced as was the amount of β-endorphin. Thus, TRPM3 may not only be important for the 
release of α-MSH but also for the release of β-endorphin.    
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